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Sommario 
L’Atrofia Muscolare Spinale (SMA) è una patologia neuromuscolare 
autosomica recessiva che colpisce i motoneuroni, ed è, ad oggi, la prima 
causa genetica di mortalità infantile. E’ causata da mutazioni in omozigosi del 
gene Survival Motor Neuron 1 (SMN1), che danno luogo alla produzione di 
insufficienti livelli della proteina SMN. 
Da un punto di vista patologico, la SMA è caratterizzata da una perdita 
progressiva dei motoneuroni (MN) nelle corna anteriori del midollo spinale a 
cui consegue una perdita delle funzioni muscolari, paralisi e morte prematura. 
Da quest’ anno è stato approvato il primo farmaco per la SMA, Nusinersen, un 
oligonucleotide antisenso (ASO). Infatti, una delle possibili strategie che 
permettono di aumentare i livelli di proteina SMN funzionante è l’uso di ASO in 
grado di modulare lo splicing dell’mRNA di SMN2, il gene paralogo di SMN1. 
Attualmente sono utilizzati in trial clinici ASO con diverse strutture chimiche, 
inclusi gli ASO con una chimica di tipo Morfolino (MO) studiati in questo 
lavoro. Gli oligomeri di tipo Morfolino sono particolarmente utili per applicazioni 
in vivo grazie al loro buon profilo di sicurezza ed efficacia. 
Lo scopo di questo studio è di migliorare l’efficacia del MO e di contribuire a 
risolvere il problema della sua relativa bassa biodisponibilità tissutale. Infatti gli 
ASO in generale non riescono a superare la barriera emato-encefalica e 
devono essere somministrati attraverso un’iniezione relativamente invasiva 
intratecale nel liquido cefalorachidiano per raggiungere il sistema nervoso 
centrale. 
In primo luogo, per migliorare l’efficacia degli oligomeri di tipo MO, abbiamo 
testato nuove sequenze di MO che si appaiano alla regione identificata come 
intronic splicing silencer N1 (ISS-N1) di SMN2 sia in vitro che in un modello 
murino transgenico di SMA (SMA7). 
L’uptake cellulare e tissutale e i profili farmacologici degli ASO possono essere 
migliorati in modo significativo attraverso la loro coniugazione con cell-
penetrating peptides (CPP), ovvero peptidi che riescono a penetrare nelle 
membrane cellulari, ma questo approccio non è ancora stato utilizzato nella 
SMA. Quindi, come seconda fase dello studio, ci siamo proposti di valutare un 
III 
 
approccio terapeutico per la SMA utilizzando sequenze MO coniugate a 
diversi tipi di CPP. Abbiamo testato tre diversi CPP, Tat, R6 e (RXRRBR)2XB 
che sono stati associati alla sequenza di MO [HSMN2Ex7D(-10,-34)] da noi 
già precedentemente validata. 
Abbiamo somministrato i coniugati ottenuti in modelli murini di SMA ad uno 
stadio pre-sintomatico e sintomatico della malattia per determinare il loro 
effetto terapeutico rispetto al MO non coniugato. 
Abbiamo dimostrato che l’ottimizzazione della sequenza target può migliorare 
l’effetto della correzione dello splicing attuata da MO e che l’effetto della co-
somministrazione di più di una sequenza di MO è maggiore rispetto alla 
somministrazione di una singola sequenza. Inoltre abbiamo dimostrato che i 
coniugati CPP-MO sono in grado di aumentare sia i livelli di proteina SMN nel 
sistema nervoso centrale sia la sopravvivenza media e le performance motorie 
nel modello murino SMA dopo una somministrazione intracerebroventricolare 
(ICV) e intravenosa (IV). 
I nostri risultati hanno prodotto dei dati preliminari in grado di sostenere che la 
coniugazione degli oligomeri di tipo MO ai CPP può essere una strategia 
attuabile per aumentare l’uptake cellulare dopo una somministrazione 
intratecale e per veicolare il MO nel sistema nervoso centrale dopo una 
somministrazione sistemica non invasiva. I risultati ottenuti saranno utilizzati 
per la selezione del CPP più efficiente che sarà studiato ulteriormente con 
analisi più approfondite e sarà un punto di partenza per lo sviluppo di futuri 
trial clinici. 
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Abstract 
Spinal muscular atrophy (SMA) is an autosomal recessive motor neuron 
disease and the first known genetic cause of infant mortality. It is caused by 
the homozygous mutations in the Survival Motor Neuron 1 (SMN1) gene, 
resulting in deficiency of functional SMN protein.  
The pathologic aspect of SMA is the progressive loss of Motor Neurons (MNs) 
in the ventral horn of the spinal cord, which causes the loss of muscle 
function, paralysis and premature death. 
A first drug for SMA, Nusinersen an antisense oligonucleotide (ASO) has been 
recently been approved. In fact, one of the most promising strategies in order 
to increase the SMN protein levels is the use of ASOs to redirect the splicing 
of the paralogous gene SMN2 to increase the production of the functional 
SMN protein. 
ASOs with different chemical structure are currently used in clinical trials, 
included the ASO with Morpholino (MO) chemistry studied in this work. MO 
oligomers are particularly suitable for in vivo applications thanks to their 
optimal safety and efficacy profile. 
One of the issues related to the administration of ASOs is that they are not 
able to cross the blood-brain barrier and they must be administered by 
relatively invasive intrathecal injection to reach the central nervous system 
(CNS). Therefore, we aimed to improve the efficacy of MO and to develop a 
non-invasive systemic delivery in an in vivo SMA murine model. 
First, to increase the efficacy of MO oligomers, we tested, both in vitro and in 
vivo, four new MO sequences targeting the region involved in the alternative 
splicing of SMN2 mRNA, called intronic splicing silencer N1 (ISS-N1). 
Simultaneously, to improve the delivery of MO to affected tissues, we 
conjugated it to cell-penetrating peptides (CPPs), an approach already used to 
enhance the cellular and tissue uptake and the pharmacological profile of 
ASOs, but never explored in SMA. 
We tested three different CPPs: Tat, R6, and (RXRRBR)2XB, which were 
linked to our already validated MO sequence [HSMN2Ex7D(-10,-34)]. We 
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administered the conjugates in pre-symptomatic and symptomatic SMA mice 
to determine their therapeutic efficacy versus unconjugated-MO.  
We showed that optimization of the target sequence can enhance the splice-
correction action of MO oligomers and that the effect of the co-administration 
of different MO sequences is superior to the delivery of a single sequence. 
Furthermore, we showed that CPP-MO compounds can up-regulate the SMN 
protein into the CNS of SMA7 transgenic murine models as well as their 
average lifespan and motor performance after local and systemic injection.  
Our data proved that the CPP-MO conjugates can be a suitable strategy to 
increase the cellular uptake after an intrathecal administration and to deliver 
MO oligomers to the CNS after a systemic injection. The presented results 
provided the basis for the selection of the most efficient CPPs and will set the 
stage for future clinical trials. 
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1. INTRODUCTION 
1.1 SPINAL MUSCULAR ATROPHIES 
Spinal muscular atrophies (SMAs) encompass a subset of hereditary 
autosomal recessive neuromuscular diseases characterized by an early 
onset, usually in childhood, and a selective and progressive death of 
lower motor neurons in the brainstem and spinal cord. As a 
consequence of this loss, patients affected by this disease show a 
progressive proximal muscle weakness, atrophy and paralysis, which 
are usually symmetrical.  
The heterogeneity of these atrophies are due to the variability of clinical 
features (age of onset, severity of the disease and pattern of muscular 
involvement) and of genetic features (causative gene defect and 
transmission mode). 
The most common form, which belongs to Proximal Muscular Atrophy 
with childhood onset, is an autosomal recessive disease (SMA5q, 
OMIM #253300) with an incidence of 1 in 6000 to 1 in 10000 live births, 
with a carrier frequency of 1/40-1/60 60 [1, 2]. The genetic cause was 
found in a mutation or homozygous deletion in the telomeric copy 
(SMN1) of SMN (Survival Motor Neuron) gene, on 5q chromosome, 
which causes a depletion of SMN protein[3].  
In the following study we will analyze the SMA5q. The typical clinical 
aspects present in SMA5q are generalized muscle weakness and 
atrophy. The pathology is characterized by a progressive and 
symmetrical muscle involvement, weakness and atrophy resulting in 
the loss of voluntary control of limbs and trunk movements, postural, 
swallowing and breathing. The intellectual functions are conserved and 
there is no involvement of sensory neurons. 
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From the analysis of patients’ tissues, there is an evident sign of gliosis 
in the absence of demyelination by the anterior horn of the spinal cord 
and reduction in motor neurons number. Surviving motor neurons show 
both signs of degeneration, indicating an ongoing process of neuronal 
death, and signs of immaturity: they have a small size, are pyknotic, 
and have the Nissl substance poorly developed. Axons analysis at the 
level of the ventral roots show axons surrounded by a single Schwann 
cell, a lower density and a high percentage of poorly myelinated axons, 
while in the neuromuscular junctions neurofilaments aggregates are 
detected at the presynaptic level. The motor plates are smaller and 
structurally underdeveloped. Muscle biopsy also shows groups of 
hypertrophic fibers in a more general atrophic context. 
 
1.1.1 HISTORY OF THE DISEASE 
In 1891, Werdnig and Hoffman described SMA, asserting that the key 
pathological features of the disease were the atrophy of skeletal 
muscles and degeneration of lower motor neurons (MNs) in the anterior 
horns of spinal cord. Lately, respectively in 1899 and 1903, Sylvestre 
and Beevor described the severe form of SMA[4].  In the 1950s, milder 
form of SMA have been described: they were characterized by 
conserved ability to walk until adult life and prolonged lifespan. 
In 1995, Lefebvre and colleagues discovered the disease-causing gene 
of SMA [3], making the diagnosis of the pathology possible through a 
simple molecular blood test, leading to the enhancement of early 
diagnosis and the establishment of standards of care for patients [5, 6]. 
The causative gene of SMA disorder was found in the survival motor 
neuron (SMN) gene [3] on chromosome 5q13 [7]. After a finest genetic 
characterization of the disease, it was described that the human 
genome harbors two forms of SMN gene encoding for the same 
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protein: a telomeric form (the SMN1 gene) and a centromeric form 
(SMN2 gene). The coding sequence of SMN2 gene differs from the one 
of SMN1 gene for few nucleotides and in particular for a C to T 
substitution in position 840. This change is essential for the 
transcriptional step. In fact, the transcription of SMN1 gene produces a 
full-length mRNA, which is translated in a full-length, functional SMN 
protein, while the C to T transition in SMN2 leads to the exclusion of 
exon 7 from the majority of SMN2 transcripts, causing the production of 
a truncate form of SMN2 protein, which is not functional and rapidly 
degraded into the cytoplasm. Only a small percentage (10%-15%) of 
SMN2 transcript incorporates the exon 7 and it is translated in a 
functional full-length SMN protein.  
Further analysis showed that the number of copies of SMN2 is 
inversely proportional to the severity of the disease [8]. Even if the SMA 
phenotype is primary related to the number of SMN2 copies, there are 
also other genetic variations that can modify and modulate it. There is, 
for example, a G to C substitution at the 859 position in the SMN2 gene 
which increases the number of SMN2 transcripts that retain exon 7. 
The increase of full-length SMN protein is associated with milder 
manifestations of the disease, even in the presence of only two copies 
of SMN2 [9]. 
 
1.1.2 CLINICAL CLASSIFICATION 
SMA 5q is clinically classified into four groups, according to the age of 
onset and the highest motor function achieved by affected subjects 
(Table 1). A fifth group (type 0) has been added to describe as a 
severe form characterized by pre-natal onset and death within 3 weeks 
after birth[10]. 
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SMA 
TYPE 
AGE OF 
ONSET 
HIGHEST MOTOR 
FUNCTION 
ACHIEVED 
LIFE EXPECTANCY 
Type 0 Pre-natal None Less than 1 month 
Type I 0-6 months Never sit unassisted Less than 2 years 
Type II 7-18 months Can sit unassisted 
Between 2 years and 4 
years 
Type III 
After 18 
months 
Can stand and walk 
unaided 
Normal life expectancy 
Type IV 
Second or 
third decade 
Can stand and walk 
unaided 
Normal life expectancy 
 
Table 1: Clinical classification of SMA 
This classification has several clinical advantages, even though SMA 
patients do not have all the characteristics of a specific type, so 
prognostic information cannot be constantly extrapolated. 
• Type I (OMIM 253300): named Werdnig- Hoffman disease, is the 
most common and severe form. Infants never gain the ability to sit 
unsupported. The head control is usually missing.  
• Type II (OMIM 253550): named Dubowitz Disease, is the intermediate 
chronic infantile onset form. Affected children reach the ability to sit 
without any support and some of them could be stand, although they 
cannot walk. 
• Type III (OMIM 253400): named Wohlfart-Kugelberg-Welander 
disease, is the mild chronic juvenile onset form. Patients reach the 
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ability to walk unaided, and some of them could never need wheelchair 
assistance during childhood. 
• Type IV (OMIM 271150): is the form that presents in adulthood. 
Patients have the ability to walk and no problems related with 
respiration and nutrition are observed. 
 
1.2 GENETIC AND MOLECULAR FINDINGS 
For the first time, in 1990, the causative gene of SMA was mapped in a 
complex region of chromosome 5q (5q11.2-13.2) which contains an 
inverted duplication [7, 11]. In 1995, the Survival Motor Neuron (SMN) 
gene, which is located in that region, was identified as responsible for 
the disease[3, 12, 13].In the human genome, there are two almost 
identical SMN gene on chromosome 5q13: the telomeric or SMN1 
gene, which is the SMA causative gene, and the centromeric one or 
SMN2 (Figure 1). 
 
Figure 1:  Locus of SMA causative gene, localized in a complex region of chromosome 
5q (5q11.2-13.2). 
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This region may be subjected to intrachromosomal rearrangements as 
gene duplication, conversion or de novo deletions. Homozygous SMN1 
deletions of exons 6-8 are the usually involved mutations; however, 
frameshift, missense and nonsense SMN1 variants have also been 
proved as responsible for SMA [14]. 
 
1.2.1 SMN GENE 
The SMN gene is composed of nine exons (exon 1, 2a, 2b, 3-8) and 
eight introns and it covers a genomic region of about 20 kb with the 
stop codon located at the end of exon 7. The difference between the 
sequence of the two genes is the substitution of only 5 nucleotides 
(Figure 2), of which one is located in the coding region of the gene 
[15].  
The SMN1 gene encodes a homonymous 38 KDa protein of 294 
aminoacids which is ubiquitously expressed in human somatic tissues. 
While SMN1 gene is highly conserved in species from yeast to man, 
SMN2 gene is only found in the human genome [16]. 
SMN is required for life considering the fact that every patient has an 
homozygous mutation, rearrangement or deletion in the SMN1 gene, 
but at least one copy of SMN2 gene [17]. The severity of the disease 
phenotype is mainly related to the number of copies of SMN2 that each 
patient retains. Two copies of SMN2 usually determine SMA type I [18], 
three copies determine SMA type II and three or four copies of SMN2 
determine SMA type III or IV[19, 20]. Patients with more than 5 copies 
of SMN2 show no sign of SMA even if they lack SMN1 [21]. In fact, 
about 10% of full length transcripts are produced by every copy of 
SMN2, and consequently the increased expression of protein SMN-FL 
is due to SMN2 gene, which is a benefit for patients. 
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From a molecular point of view, SMN2 is subjected to a particular 
process called alternative splicing, which occurs during the 
transcription. The alternative splicing of SMN2 pre-mRNA produces an 
mRNA lacking of exon 7 or, rarely, exon 5 or both exons. The exclusion 
of exon 7 from the mRNA of SMN2 is caused by a single C>T 
substitution in position +6 of this exon [22]. Despite being a silent 
mutation, which does not alter the amino acid sequence of the 
translated protein, it is localized at the level of an exonic splicing 
enhancer and therefore removes exon 7 during the transcription. In 
2002, Cartegni and Kranier supported the hypothesis that the 
substitution C>T in exon 7 alters the sequence of an Exonic Splicing 
Enhancer (ESEs), suppressing its function. The exon 7 of the SMN 
gene is characterized by a weak splice site 3'. The inclusion of exon 7 
in mRNA is positively regulated by many exonic factors in cis, called 
intronic splicing enhancer, while it is negative regulated by exonic 
elements in cis called Exonic Splicing Silencers (ESSs) or Intronic 
Silencers (ISSs). All of these cis elements (Figure 2) are recognized by 
transacting splicing proteins rich in serine-arginine (SR proteins) and 
several heterogeneous nuclear ribonucleoprotein (hnRNPs) [23]. 
 
 
Figure 2: Splicing architecture of exon 7 of SMN gene: multiple RNA elements 
influence alternative exon 7 recognition.  
 
In exon 7, the exonic splicing enhancer binds the Splicing Factor 2 
(SF2), also named alternative splicing factor (ASF). SF2, in order to 
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form the splicing complex involved in the intron 7 removal from SMN1 
pre-mRNA, binds in turn the U2 class of small nuclear ribonuclear 
protein (U2 snRNP) and the U2 auxiliar factor (U2AF).  
A second hypothesis proposed in 2003 by Kashima and Manley argued 
that the substitution C > T in SMN2 generates an ESS that interacting 
with hnRNP A1 facilitates the exon 7 skipping. This theory is supported 
by the knockdown of hnRNP A1 by siRNA (small interfering RNA) 
which induces an increase in exon 7 inclusion [24]. These two models 
are not necessarily incompatible and a third hypothesis, joining the two 
above-mentioned mechanisms, explain the alternative splicing of SMN 
transcript in a dual mechanism that includes both the loss of a specific 
ESE for SF2/ASF and the simultaneous creation of a specific ESS for 
hnRNP A1 [25]. The most important intronic splicing regulator of introns 
6 and 7, is ISS- N1 which exerts a powerful effect on the activity of 
other positive elements in cis of exon 7 and intron 7. Antisense 
oligonucleotides against ISS- N1 determine the inclusion of exon 7 in 
the majority of SMN2 mRNA transcripts [26]. 
According to another study, an exonic splicing suppressor [25] 
promotes the binding of heterogeneous nuclear ribonuclear protein A1 
(hnRNP A1) or splicing suppressor protein, and sterically obstruct the 
formation of the splicing complex or its stabilization [24]. Even if the two 
hypotheses have been tested, the exact mechanism of the exon 7 
exclusion remains an unsolved question (Figure 3). 
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Figure 3: Alternative splicing process of the SMN1 and SMN2 pre-mRNAs. The C6T 
substitution within SMN2 causes the removal of exon7 from about 90% of the SMN2 
mRNAs 
 
A greater understanding of this mechanism will surely lead to a 
significant progress in the possible therapeutic approaches for SMA 
disease. 
Despite the different mechanism, SMN1 gene produces a full-length 
(FL) transcript that undergoes to a correct splicing in almost 100% of 
cases, while SMN2 produces only 10% of the transcript FL and in 90% 
of cases produces a transcript missing exon 7 (SMNΔ7). The full length 
mRNA SMN1 and SMN2 genes coding for identical proteins of 294 
amino acids, while the transcript missing exon 7 (isoform SMNΔ7) 
encoding for a truncated protein of 282 aa which is unstable and has a 
reduced ability to oligomerization; this results in a lower functionality of 
the protein and an early degradation [27] (Figure 4). 
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Figure 4: The Survival Motor Neuron Genes SMN1 and SMN2 have an identical 
structure and are 99.9% identical at the sequence level. The difference between the 
two genes is a single-nucleotide change in exon 7 (C or T). This single nucleotide 
change affects the splicing of the gene, so most SMN transcripts from SMN2 lack exon 
7, whereas those from SMN1contain exon 7. The loss of the amino acids that are 
encoded by exon 7 results in the production of an SMN protein with severely decreased 
oligomerization efficiency and stability, and the SMN monomers are rapidly degraded. 
In a minority of cases, SMN2 transcripts contain exon 7 and encode for a normal, full-
length SMN protein. 
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SMN2 gene produces only a small fraction of functional SMN protein 
than its homologous telomeric counterpart, insufficient for normal 
survival of motor neurons [28, 29]. 
 
1.2.2 SMN PROTEIN 
SMN genes encode for the evolutionarily conserved and ubiquitously 
expressed 38 KDa SMN protein. This protein, which is particularly 
abundant in motor neurons of the spinal cord, is localized in the 
nucleus and in the cytoplasm of cells. There are particular structures 
inside the nucleus of the cells through which SMN protein is visible in 
association with coiled bodies (or Cajal bodies). These structures are 
called Gems (Gemini of coiled bodies) and their presence is a mark for 
cells of healthy patients, while in cells of patients affected by SMA their 
number decreases [30]. 
SMN forms a complex with gemini 2-8 and regulates the assembly of 
small nuclear ribonuclear proteins (snRNPs) [31, 32]. snRNPs are 
complexes of RNA-proteins that take part in the formation of the 
spliceosome.  
The spliceasome, which is responsible for the splicing of the new 
synthetized pre-mRNA, is very active during the embryonic and post-
natal development, while it is less active when myofibers and neurons 
are fully differentiated [33]. 
There are two main hypotheses to link the lack of SMN protein and the 
MN degeneration. The first one involves the impairment of the snRNPs 
complex. According to this hypothesis, when the normal splicing does 
not occur, the functions and survival of MNs are compromised. It has 
been demonstrated that when the levels of SMN protein are low, there 
is a lack of U11 and U12 snRNPs which constitute the minor 
spliceasome, responsible for the splicing of a minority of introns [34]. 
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Some of them are mainly expressed in the nervous system and encode 
for essential neuronal component, like synaptic components and 
voltage gated ion channels. 
The second hypothesis is based on the specific role that SMN protein 
could have for MNs, such as mRNA transport along the axons [35]. 
Furthermore, SMN protein seems to be involved in the membrane 
remodeling of MNs, which is very specialized for its extreme polarity, 
for the extension of the cellular processes and for the presence of 
neuromuscular junctions (NMJs). These data suggest that SMN is 
involved in MNs function and viability through the regulation of axonal 
transport, the remodeling of membrane domains and the preservation 
of NMJs’ structural activity. 
 
1.2.3 ANIMAL MODELS OF SMA 
In order to understand the causes and the pathological hallmarks of the 
disease and to develop therapeutic strategies for clinical trials in 
humans, the use of animal models is fundamental. 
So far, the models of SMA have been obtained in different species. 
One of these is Drosophila, in which the human mild form of SMA has 
been reproduced, through a point mutation in the SMN1 gene [36]. Due 
to the high reproducibility of the animal, this model is very useful for a 
large scale screening of therapeutic molecules. 
Another animal model used is Zebrafish [37]. When the SMN gene is 
downregulated through antisense oligonucleotides (ASOs), it is 
possible to observe neural structural abnormalities and MN apoptosis 
of MNs, similar to those found in humans. Thanks to the easy 
manipulation and the transparency of its body, Zebrafish is very useful 
for the study of SMN in pre-natal and post-natal development, and for 
the first step for large scale in vivo drug screening [37]. 
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1.2.3.1 MURINE TRANSGENIC MODELS 
The murine model represents the model closer to the human pathology 
and more useful to the clinical research. Mice harbor a single copy of 
the SMN gene. If SMN gene is disrupted in homozygosis, there is a 
failure of early development of mice embryos and pre-natal death [38].  
Different transgenic SMN -/- mice have been generated, carrying one 
or more copies of the human SMN2 gene (Table 2). The severity of 
their phenotype is inversely correlated with the number of SMN2 
copies. 
The most commonly used murine models are: 
- Smn1-/-; SMN2tg/tg; SMNΔ7tg/tg (usually identified as SMA∆7 
mouse) [39] 
- Smn1hung-/-;SMN2Hungtg/tg (Hung-Li model) [40] 
The first available model of type II SMA was the Hung-Li model. It has 
a homozygous null mutation in the murine SMN gene and harbours a 
full-length human SMN2 transgene. 
After another model was developed by Monani et al. that resembles 
SMA type I, carrying a homozygous null mutation in the SMN gene and 
the human SMN2 transgene [41]. The signs of the pathology are a 
motor impairment from post-natal day 2 (P2), the loss of about 40% of 
lower MNs and the death around P5.  
The same investigators created another transgenic mouse model 
showing an intermediate SMA type I/II phenotype, adding the cDNA of 
the human SMN2 lacking exon 7 to the previous model [39]. 
This model starts to present signs of muscle weakness at P5, loses 
about a half of lower MNs and dies at 13 days of age. Before the 
decline of motor functions, the first alteration is the structural 
abnormality of NMJs, which are not completely mature and are not able 
to cluster the acetylcholine receptors. 
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Another mouse model developed by Monani et al., called SMN1A2G, 
resembles SMA type III in humans because it carries a SMN1 
transgene with A2G missense mutation [42]. 
Despite all these mouse models, SMA∆7 is the one which is commonly 
used because it reproduces better the human SMA phenotypic 
characteristics. 
The only issue related to these mice is the limited lifespan which not 
allow to evaluate some therapeutic approaches. 
 
Model 
Name 
Genotype 
SMA 
type 
Life 
expectancy 
Phenotype 
Smn1 null 
mutation 
Smn -/- Type I 
Pre-natal 
mortality 
Severe 
Hung-Li 
mouse 
Smn1hung-/-
;SMN2Hungtg/- 
Type II 13 days 
Intermediate: Similar to 
the ∆7 mouse model. 
∆7 mouse 
model 
 
Smn1-/-; 
SMN2tg/tg;SMNΔ
7tg/tg 
 
Type II 13 days 
Intermediate: Muscle 
weakness is present 
from P5 and progress 
over time, abnormal 
gait, tendency to fall. 
ByP9 around 50% of 
LMNs are lost. 
A2G 
mouse 
Smn1-/-; 
SMN2tg/tg;SMN1
A2G 
Type III 
Less than 1 
year 
Mild: Milder than the 
Δ7 mouse. Decreased 
body weight, muscle 
atrophy and weakness. 
 
Table 2: commonly used SMA murine models 
 
1.3 DIAGNOSIS 
1.3.1 GENETIC COUNSELING AND PRENATAL DIAGNOSIS 
The screening test generally used to detect SMA is a semi quantitative 
real time PCR or MLPA, recognizing the heterozygous deletion of one 
SMN1 allele, as the most frequent mutation is the homozygous 
absence of SMN1 gene. 
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There are some limits of the prenatal diagnosis process that cannot 
establish an accurate prognosis, indeed the severity of the potential 
affected fetus might not be predict a priori and the SMN2 number of 
copies is not sufficient to establish an accurate prognosis. 
The importance of the prenatal diagnosis is to identify affected infants 
before the onset of clinical symptoms. Even if a number of potential 
therapies are in clinical trials [43, 44], their success depends on the 
early identification of affected subjects, in order to administer the 
treatment before potentially irreversible neuronal loss. 
 
1.3.2 MOLECULAR DIAGNOSIS 
 When disease phenotype is very severe, the diagnosis of SMA can be 
highly suspected from clinical features. 
The first step for the molecular diagnosis is the detection of a 
homozygous deletion in SMN1 [5]. A Restriction Fragment Length 
Polymorphism (PCR-RFLP) test is performed to analyze the absence of 
SMN1 exon 7 (with or without deletion of exon 8). The sensitivity of this 
analysis is 95% but it is not able to identify carrier subjects. If this first 
test is negative, some other laboratory exams are performed. 
Generally, when a single SMN1 copy was found in a patient, coding 
region of the undeleted allele is sequenced to identify the second 
causative mutation, generally point mutations, insertions and deletions. 
It has been observed that one third of patients with a single SMN1 copy 
and a typical phenotype of the disease does not show the second 
mutation in SMN1/SMN2 coding region, especially in mild form of SMA 
(SMA III). The explanation could be found in the presence of deep 
intronic mutations, which are so far unpublished. 
Usually when patients are born from consanguineous parents and have 
a typical clinical picture, are highly recommended to have a sequence 
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analysis of SMN1 gene, while, in patients with 2 SMN1 copies, other 
neuron disorders should be considered and SMA diagnosis related to 
SMN1 mutations is virtually excluded. 
 
1.4 THERAPEUTIC STRATEGIES FOR SMA 
The discovery of molecular basis of SMA was a critical step to develop 
possible different therapeutic approaches [45]. Furthermore, the 
availability of animal models showed a correlation between the disease 
and the low expression of SMN gene. There are different approaches 
used as therapeutics for SMA and many of them are under evaluation 
in human clinical trials (Figure 5).  
 
Figure 5: Current status of investigational drugs for SMA. Modified from Curesma.org 
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These approaches are based on different techniques such as the 
replacement of the mutated SMN1 gene, the modulation of SMN2 
splicing and expression or the protection of MNs from degeneration. 
On December 2016, the first therapy for SMA based on the splicing 
correction, named Spinraza, has been approved by FDA, followed in 
April 2017 by the EMA approval. The success of this approach testified 
the importance of translational medicine. 
Overall the main investigation fields for SMA treatment can be 
classified into three groups: 
 
1.4.1 GENE THERAPY 
Gene therapy is based on the use of different viral vectors to transfer a 
functional copy of the SMN1 gene into patient’s cells, specifically into 
MNs. 
There are two strategies currently used as gene therapies: the 
replacement of SMN1 [46] and the augmentation of SMN2 read-
through. The aim of this therapy is to restore a normal form of the 
SMN1 gene in SMA patients, although the most challenging step is the 
delivery to a difficult-to-access cells, such as motor neurons. 
There is a particular viral vector with a specific tropism for the cells of 
CNS, the adeno-associated viral vectors (AAV) [47, 48]. The peculiar 
characteristic of these vectors is the ability to transduce non-dividing 
cells and to give long-term stable gene expression in order to increase 
the levels of SMN protein. 
In 2010 Kaspar group demonstrated that systemically delivered AAV9-
SMN delivered early to a severe rodent model of SMA7 results in 
substantial rescue of the lifespan. This work was published in Nature 
Biotechnology in 2010, as well as similar reports followed [49]. 
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In 2010, after the administration with an intrathecal injection of self-
complementary (sc) adeno-associated virus serotype 8 (scAAV8) 
encoding a wild type copy of the human SMN1 gene in SMA mice, 
Passini and colleagues reported an increase of the lifespan of the 
treated mice [50]. 
Moreover, the research group of Dominguez reported a rescue of motor 
function and NMJ physiology after the SMN1 delivery through scAAV9. 
The administration of the vector was done through an intravenous (IV) 
injection, and the results obtained proved that it was able to reach the 
CNS and MNs. The treated mice had a prolonged life with a mean 
survival of 200 days, compared to 13 days of the untreated mice 
[51].This vector was able to cross the BBB also in non-human primates, 
confirming its efficacy in large animals and humans [52]. 
Gene therapy has been recently evaluated in a phase 1/2 clinical trial, 
called AVXS-101 (a sc AAV9 carrying the SMN gene), on SMA type I 
subjects1.The preliminary analysis of the results of this trial are very 
promising. The survival rate of the enrolled patients increased of 100% 
at 20 months, and the motor performances improved. Some infants 
were able to sit without support, but the most positive result was 
achieved by two of the twelve infants who were treated with the highest 
dose of the vector: they are able to walk independently. 
Given these promising results, AVXS-101 was granted access to the 
EMA PRIME Program for SMA type I in January 20172. The preliminary 
data disclosed by AveXis offer positive expectation for the progress of 
gene therapy to more advanced phase trials and its clinical successful 
application. 
                                                          
1 ClinicalTrial.gov Identifier: NCT02122952 
2 AveXis, Inc.  http://investors.avexis.com/ 
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1.4.2STEM CELLS THERAPY 
Another treatment investigated in SMA is the trophic support in CNS. 
One of this strategy is based on neural stem/precursors cell 
transplantation. The first step of this approach is the differentiation of 
Embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs) 
into neural stem cells (NSCs). NSC transplantation has been tested in 
severe SMA mice and positive results in terms of increased survival 
and improved motor function have been reported [53]. 
Some properties of iPSCs for stem cell therapy make their use more 
convenient, rather than ESCs. First of all, their generation from the 
patient’s somatic cells avoids the eventual risk of rejection after 
transplantation. Then, they can be edited genetically to correct the 
SMN1 mutation [54]. IPSCs can be generated using non-viral and non-
integrating episomal vectors, that are lost over time, eliminating 
exogenous genetic sequences from the reprogrammed cells. 
In order to ameliorate the SMA mice survival and phenotype, it has 
been proved that the release of growth factors by transplanted iPSCs 
derived NSCs is the principal mechanism underlying their beneficial 
effect. 
All these positive pre-clinical results suggest that this technique 
warrants further study. 
 
1.4.3 PHARMACOLOGICAL TREATMENT 
1.4.3.1 ENHANCEMENT OF SMN2 GENE EXPRESSION 
There are some factors that influence the transcriptional activity of 
SMN2, such as CpG islands methylation of histones. Some compounds 
have been tested in order to enhance SMN2 transcription, like inhibitors 
of the histone deacetylase enzyme (HDACi) and short-chain fatty acids. 
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All these drugs were efficient in vitro but they did not show the same 
positive results in vivo [44, 55-57], probably due to the fact that they are 
active in replicating cells, but not in many mature cells like neurons. 
Another possible therapeutic approach that has been investigated is 
the inhibition of protein degradation through the proteasome. A 
proteasome inhibitor, tested in SMA mice, is bortezomib. It has been 
showed that after its administration, SMA mice improved their muscular 
functions but not their survival [58], because bortezomib could not 
cross the BBB it could not act on MNs [59]. These results highlight the 
necessity of a drug to cross the BBB and reach the CNS in order to 
improve the SMA mice survival and phenotype. 
A positive result in terms of increased amount of SMN protein in in vitro 
and in vivo studies has been obtained with quinazoline derivatives, 
which enhance the activity of SMN2 promoter [60]. 
1.4.4 SMALL MOLECULES 
The goal of the small molecules is the modulation of the alternative 
splicing of the SMN2 gene in order to produce a full-length SMN 
protein. Currently some of them are tested in clinical trials. In particular, 
Roche-Genentech/PTC Therapeutics and Novartis developed some 
molecules that have entered Phase II clinical trial RG7916 and 
LMI1070 respectively. 
RG7916 is an oral bioavailable small molecule which in preclinical 
studies showed an improved motor function and survival up to more 
than 150 day in SMA mice [61]. On October 2016, the Phase II clinical 
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trials started on patients with type II and II SMA3, while on January 
2017, a Phase II clinical trial started on patients with SMA I4. 
LMI1070 is able to enhance exon 7 retention in the SMN2 mRNA, 
stabilizing the transient double strand RNA structure formed by the 
SMN2 pre-mRNA and U1 small nuclear ribonucleic protein (snRNP) 
complex. It is currently tested in an open-label, Phase II clinical trial on 
infant with type I SMA5. 
1.4.5 ANTISENSE OLIGONUCLEOTIDES 
Another therapeutic strategy to increase exon 7 inclusion is the use of 
Antisense oligonucleotides (ASOs), short modified oligonucleotides 
which bind specific mRNA sequences (Figure 6). 
 
                                                          
3 PTC Therapeutics press release, available at: 
http://ir.ptcbio.com/releasedetail.cfm?ReleaseID=994745 
4 PTC Therapeutics press release, available at: 
http://ir.ptcbio.com/releasedetail.cfm?ReleaseID=1006620 
5 ClinicalTrials.gov Identifier: NCT02268552 
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Figure 6: Cellular internalization and steric block action of ASOs 
 
Different sequences of ASOs have been created to specifically target 
the intron splicing silencer (ISS) motif in the 5’ of intron 7 in SMN2 
mRNA [26, 62, 63]. Several ASOs with different chemical structures 
have been tested in in vitro and in vivo models, with a particular 
attention to the modifications that enhance some biological properties, 
like the stability and resistance to metabolic degradation in biological 
tissues and fluids, the toxicity and the high ability to reach the target 
cells, comprising neurons within the CNS. 
The three different ASOs chemistries tested are: 
- 2’-O-methyl phosphorothioate (2OMePS) 
- 2’-O-Methoxyethyl (MOE) 
- Morpholino (PMO) 
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The most efficient approach is the combination of a specific ASO 
sequence with an oligomer that binds positive splice activators.  
Several investigators showed that ASOs targeting the ESE altered by 
the C6T substitution within the SMN2 gene enhanced the production of 
full-length SMN in vitro [64]. This discovery was followed by a series of 
preclinical studies using 2OMePS ASO[65-73]. 
In order to promote a strong exon retention, chemically modified ASOs 
(MOE) that are resistant to endonuclease activity and are not 
dependent on RNase-H degradation have been used. ISS-N1 
sequence is so far the most important splice modulator adjacent to the 
exon 7 5’ss, involved in SMA studies. 
Several data indicated that the dosage and the early starting of the 
treatment influence the efficacy of ASO mediated therapy [68]. It has 
been confirmed that if SMA mice were treated with a low dose of MOE 
ASO with ICV injections, there was a poor effect on their survival [74]. 
There was an increase of the lifespan up to more than 500 days when 
a higher dose of MOE has been administered via multiple 
subcutaneous (SC) and intraperitoneal (IP) injections. Obviously, the 
most relevant problem connected to the use of ASOs, such as the 
limited capacity to cross the BBB, caused a significant increase of SMN 
protein levels in the peripheral tissues. 
Another important aspect to be evaluated is the safety profile of 
2OMePS and MOE ASOs. The second one was shown to be the safer 
one, while the first one caused an increase in inflammation in the spinal 
cord and a lower increase of SMN levels after the delivery into the CNS 
[75]. 
The proof that MOE ASOs are efficient and safe molecules, makes 
them suitable for human clinical trials. In fact, a MOE ASO (named 
Nusinersen, commercial name Spinraza) has been developed by Ionis 
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pharmaceutical. Administered by a lumbar puncture, it reaches the 
CNS and targets the ISS-N1 region [76, 77].  
Ionis Pharmaceutical and Biogen started a collaboration for studies in 
SMA patients. The clinical study program of Nusinersen consisted in 
two Phase III, double blind, controlled trials, identified as ENDEAR and 
CHERISH, and two additional Phase II controlled studies, called 
EMBRACE and NURTURE. 
The ENDEAR study investigated the effect of Nusinersen on SMA type 
I patients with the first treatment at 6 (or less) month old, while Cherish 
study was focused on SMA II patients between 2 and 12 years old at 
the time of screening. On November 2016, CHERISH study met its 
primary endpoint and treated patients reached an increase of 4 points 
at the Hammersmith Functional Motor Scale Expanded (HFMSE) 
respect to a decline of about 2 point of non-treated subjects. The 
EMBRACE study was conducted on SMA I and II patients who did not 
satisfy the criteria to be enrolled in ENDEAR6 and CHERISH7 studies. 
The NURTURE study is an open label trial performed on 
presymptomatic infants. None of the patients showed adverse effects 
even if the results of the Interim analysis of the NURTURE reached a 
motor milestone closer to the ones of untreated patients. 
On December 2016, Nusinersen (named Spinraza) was approved by 
the U.S. FDA as the first therapy for SMA8. The EMBRACE and 
NURTURE studies will provide knowledge about the therapeutic 
window to obtain the maximum therapeutic efficacy. 
 
                                                          
6 Biogen: http://media.biogen.com/press-release 
7 Biogen: http://media.biogen.com/press-release 
8 Biogen: http://media.biogen.com/press-release 
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1.4.5.1 MORPHOLINO 
A particular type of ASO is Morpholino (MO) in which the 
phosphorothioateribose backbone is replaced by phosphorodiamidate-
linked morpholine backbone that is refractory to metabolic degradation 
(Figure 7). 
 
Figure 7: Chemical structure of MO ASOs  
 
The low toxicity of this compound has been proved in preclinical studies 
and its ability to not elicit the immune response makes it interesting for 
in vivo uses, in particular in clinical trials, such as what was already 
tested for Duchenne Muscular Dystrophy [78, 79]. 
These characteristics make it a suitable candidate for molecular 
therapy in SMA. However, there are several issues to be addressed, 
such as its sequence and the modalities of its administration. In fact, it 
is not clear if a local injection is sufficient to rescue the SMA phenotype 
[80] or if a systemic injection is necessary and sufficient [74]. 
The MO’s mechanism of action is based on a steric block, that hampers 
the mRNA translation. The length of MO oligomers is crucial for their 
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function. Burghes and colleagues tested MOs with different length 
(20,22 and 25 mers) and they demonstrated that the MOs’ length is 
directly correlated to the efficiency in human SMA fibroblast [81]. 
Another characteristic that influences the efficacy of MO is the position 
of the target sequence within ISS-N1. The most consistent effect was 
achieved when targeting 8-35 base region of intron 7 [82].Once 
reached the optimal length, the same group conducted dose escalation 
studies and showed that the optimal length is 25 mer (MO-10-34) 
because this MO can exert its action even when it is administered at 
lower doses. 
Other in vitro studies confirmed that MO-10-34 is the most efficacious 
sequence and for this reason it has been tested in vivo. When 
homozygous SMA-∆7 mice were treated with MO-10-34, a splice-
correction was observed and the mean survival was extended (>120 
days) [82]. 
The big challenge of this strategy is to avoid the ICV administration, 
necessary because of the scarce bioavailability and concentration of 
MO in the CNS after the systemic injection. For this reason, our group 
evaluated the efficacy of MO-10-34 sequence, synthetized as 
unmodified MO oligomers (bare-MO) or octaguanidine-conjugated MO 
(Vivo-MO) to test their efficacy on survival and motor function of SMA 
mice [83]. The results obtained showed that Vivo-MO is capable to 
cross the BBB thanks to its guanidinium group, respect to bare MO. 
After the treatment of SMA∆7 pups with systemic and local injections, 
we determined that Vivo-MO is as efficacious as bare-MO but more 
toxic, limiting the maximum dose achievable. Moreover, the combined 
treatment of intracerebroventricular (ICV) and subcutaneous (SC) 
injections at the maximum dose of 12 nmoles per injection, improved 
mice survival and motor function respect to lower doses and to the local 
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or systemic injections alone. Our results suggested that if there is an 
increase of SMN protein levels in tissues outside the CNS, it could 
improve the motor performance and the survival rate and the 
optimization of MO sequence with its systemic delivery are crucial 
issues to optimize this therapeutic strategy. 
 
1.5 DRUG DELIVERY TO THE CENTRAL NERVOUS 
SYSTEM 
One of the limiting steps for the systemic delivery of a drug in the 
treatment of neurological disease is reaching the CNS. The CNS has 
innate physiological barriers that protect it from toxins and infections. 
These barriers are the BBB and the blood-cerebrospinal fluid barrier 
(BCSFB). 
The main characteristic of this area is that the lipophilic molecules with 
a molecular weight of maximum 600 Da can pass through it by free 
diffusion, while the larger or hydrophilic molecules are transported with 
active systems, by carriers or receptors[84].  
The positively charged molecules can enter the CNS by an endocytic 
pathway, called absorptive-mediated transport [85]. 
The highly selectivity of this barrier has a double effect: if from one side 
it protects and supports the function the CNS, on the other side it is a 
challenging obstacle to drug delivery. This is the reason why the proper 
design of drugs is a very important step in the treatment of neurological 
diseases. 
1.5.1 CROSSING THE BLOOD-BRAIN BARRIER 
The ability of a drug to cross the BBB depends on its physical and 
chemical properties, like size, structure, lipophilicity, molecular weight, 
volume of distribution and affinity for receptors or efflux pumps. Some 
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approaches to cross the BBB in a non-invasive way could be the 
generation of: 
• chimeric peptides 
• viral vectors 
• liposomes 
• cell-penetrating peptides (CPPs) 
• nanoparticles (NPs) 
• dendrimers. 
We will discuss below the importance of CPPs in our study.  
1.5.2 CELL-PENETRATING PEPTIDES 
1.5.2.1 DEFINITION AND CLASSIFICATION 
Some of the problems that prevent several therapeutic strategies to be 
efficiently translated to the clinic are the biodistribution, the 
bioavailability and the pharmacokinetic of the drugs/molecules used in 
neurological diseases. In fact, the design of molecules that can cross 
the BBB, reaching their target site, is a critical step in 
neurodegenerative disorders. 
Over the last 20 years, more than 100 peptidic sequences of 5-40 
amino acids have been identified to promote the drug delivery [86]. 
These peptides, also named as Cell-penetrating peptides (CPPs), can 
cross biological membranes and translocate into the intra-cellular 
compartment [87, 88]. Their main advantage is their ability to delivery 
different compounds, such as proteins [18, 19] nucleic acids, siRNA 
[89], nanoparticles [20] and ASOs, across biological barriers. 
The CPPs have different physical-chemical properties and they can be 
divided in three major classes: cationic, amphipatic and hydrophobic. 
Most of them have a net positive charge (83%), anionic CPPs are 
assigned to different classes according to their basis, the amphipatic 
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CPPs form a large class (44%), and the hydrophobic are only 15 % [90, 
91]. 
• Cationic class: this is the biggest class to which belongs the best-
known CPP derived from HIV-1 protein TAT (TAT peptide). The 
arginine-rich sequences require a minimum amount of eight arginine 
residues named octaarginine (R8) for cellular uptake [92]. The 
ability of arginine residues to penetrate cells at physiological pH is 
an important characteristic for the transduction of these peptides. 
The ability of these peptides to cross the biological barriers has 
been developed by increasing the space between guanidinium 
groups and the backbone of synthetic peptides [93] or conferring a 
cyclic structure [94]. Moreover, these short cationic sequences 
develop electrostatic interactions with negatively charged 
glycoproteins on cellular surface and they can be used as 
transmembrane carriers for therapeutic compounds [87]. 
• Amphipathic class: in this class we can find peptides as MPG and 
Pep-1, or peptides derived from natural proteins as pVEC and 
secondary amphipathic α-helical CPPs in which hydrophobic and 
hydrophilic aminoacids are placed in different faces of the helix as 
MAP peptide and Transportan.  
• Hydrophobic class: peptides based on natural aminoacids or 
chemically modified petides belong to this class. They seem to 
directly cross the cell membrane avoiding endosomal degradation. 
Moreover, according to their origin, CPPs are classified as derived from 
natural proteins or synthetic polypeptides. To the first group belong the 
peptides that are able to pass through biological membranes. After this 
discover, chimeric peptides were designed in order to be used as 
biological carriers [95].  
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Artificial peptides are synthetized replacing natural amino-acids, 
generating chimeric sequences. They are classified according to their 
chemical structure and physical features. 
Despite their classification, CPPs are very useful as a tool for drug 
delivery in neuromuscular disorders, being able to cross biological 
membranes and releasing therapeutics biomacromolecules in the 
target site (Figure 8). 
 
 
 
 
Figure 8: Cell-Penetrating Peptides. Applications as molecular delivery vehicles for a 
variety of drugs, nucleic acids, proteins, therapeutics and imaging agents and uptake 
mechanisms. 
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1.5.2.2 MECHANISMS OF INTERNALIZATION 
Short, positive charged CPPs, interacting with the negatively charged 
BBB, increase cellular drug uptake and activate the permeabilization of 
cell membranes, stimulating the endocytosis of the cargo [96]. 
Endocytosis is a natural, energy dependent, cellular process which 
consists of electrostatic interactions with proteoglycans at cellular 
surface or involves direct destabilizing interactions across the lipid 
bilayer [90]. 
The peptides that constitute the CPPs interact with the proteoglicans in 
the cell membranes [97, 98] and this step is critical for the activation of 
a downstream signal pathway, inducing the pinocytosis [99]. 
Another mechanism used by CPPs to cross the membranes is called 
transduction. It is an energy independent pathway based on direct 
membrane penetration, using a pore formation model [90]. This 
mechanism of internalization requires a conjugation between the 
peptide and small molecules. 
Even if different modalities of cell penetration can happen, endocytosis 
is the most important and clinically relevant one [100]. 
1.5.2.3 APPLICATIONS OF CPPs 
In the recent years, CPPs have been used as a delivery tool taking 
advantage of their safety profile in in vitro and in vivo models. The 
principal applications of CPPs in the delivery of molecules of 
pharmacological relevance are following presented. 
1.5.3 SMALL INTERFERING RNA (siRNA) DELIVERY 
Despite being useful in the pharmacological field through gene 
silencing, siRNAs lack of a safe and efficient delivery that allow them to 
step into the clinical practice [101, 102]. When they are conjugated with 
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CPPs, they are successfully delivered both in in vitro and in vivo 
systems. There are different conjugation approaches: the simpler one 
consists on a non-covalent bonding between siRNAs and CPPs [89, 
103]. The complexes obtained show a net positive charge. The use of 
oligo-arginine peptides reported good results in terms of siRNA delivery 
in vitro [104] and in vivo [105]. Another interesting strategy is the 
generation of a chimeric peptide composed by the protein transduction 
domain of the TAT peptide and a double strand RNA binding domain. 
This method tested by Eguchi et al.[106] has the advantage not to 
cause the activation of the immune system. 
However, the better strategy seems to be the covalent bonding 
because it is easily reproducible and allows a precise stoichiometry of 
conjugates obtained and siRNA-CPP proportion [89]. 
The negative aspect of this technique is the higher concentration 
needed to achieve efficient gene silencing [107]. This situation was not 
observed when not purified siRNA-CPP complex have been used [108-
110]. The reason has been found in the fact that the unpurified 
solutions are rich of covalently bound complexes, which can derive 
from the excess of siRNA and CPPs in the reaction [111]. Anyway, 
promising results were obtained with covalent bonding between siRNA 
and TAT [108], transportan [109] and penetratin [110]. 
There are several clinical trials ongoing or completed9, but none of 
them seem to solve the bioavailability issue. Indeed, all these trials use 
saline-based solutions of siRNAs. 
                                                          
9 Registered Clinical Trials were searched on www.ClinicalTrials.gov using the 
keywords smallinterfering RNA or the abbreviation siRNA. 
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1.5.4 DNA DELIVERY 
An alternative of viral vectors for gene delivery is represented by CPPs 
[23]. Despite being widely used, viral vectors have some issues still 
unresolved [28]. After their use, we can observe toxicity, 
immunogenicity, and a restriction in the length of genes that can be 
packed into them. Another problem is the risk of inducing oncogenic 
mutation, as they can randomly be integrated into the host genome 
[28]. 
An alternative strategy for the gene delivery is the use of nanoparticles 
and liposomes [31, 45]. 
To date, CPP-based gene delivery has been evaluated in vitro and in 
vivo. Data showed good results of gene expression in both cell cultures 
and animal models [82, 112, 113]. In order to increase the transfection 
efficiency, different cationic CPPs have been chemically modified. Such 
modifications include stearic acid modification of arginine rich peptides 
TAT, REV, polyarginine with 4 to 16 amino acids, RxR4 [84, 85, 114]. 
Among them, TAT peptides produced controversial results. In fact, the 
lacking efficiency obtained in vivo did not correspond with the high one 
reported in vitro. The reason of this incongruity is probably caused by 
the poor in vivo stability of the CPPs and their poor resistance to 
metabolic degradation, due to the presence of serum proteins and 
peptidases. 
To overcome this problem, one possible strategy is to use multivalent 
ramified structures, as reported by Lo et al. [115]. They used a 
structure harboring 1 to 8 TAT peptides with the addition of multiple 
histidine and cysteine residues that increased transfection efficiency 
[116]. 
Another good result has been obtained with the use of non-viral vector-
CPP conjugates [117]. Some of them are made of CPPs linked to PEI, 
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PEG- PEI [118, 119],or  liposomes [120] and non-covalent complex of 
DNA, liposomes and CPPs (lipoplex) [121, 122]. 
The efficiency of lipid vectors has been boosted with this approach in in 
vivo models. One positive aspect of this method is that CPPs allow the 
penetration of liposomes and their cargo into the cells, while liposomes 
protect the drug and keep it from the degradation until it reaches the 
cellular target. 
1.5.5 ANTISENSE OLIGONUCLEOTIDES DELIVERY 
The main issue that obstacles the use of ASOs in clinic is their poor 
bioavailability.  
In 1998, Pooga et al. [123] demonstrated the efficacy of CPP-ASO 
conjugates in vitro and in vivo. In the following years, CPP-ASOs have 
been used to treat Duchenne Muscular Dystrophy (DMD) by an exon 
skipping approach [79]. In particular, several studies on DMD animal 
models showed that the best used CPPs were arginine-rich CPP such 
as (RXR)4 [124] and (RXRRBR)2 [125]. These conjugates were 
effective in inducing exon skipping in vivo and showed a dose-related 
response in dystrophin restoration. After the treatment, it has been 
observed an amelioration of the disease phenotype due to the 
presence of a functional dystrophin protein in several muscles. 
Moreover, these studies did not report significant signs of toxicity. 
In the last years, a new class of arginine-rich CPPs named “Pip” have 
been investigated in murine models of DMD [126-128]. The structure of 
these peptides is made of a hydrophobic core and the external faces 
are positively charged with arginine residues. The interesting result 
obtained after the use of these peptides is that ASO conjugated to 
Pip5e and Pip6a were highly effective when they are administered at 
very low doses. These data support the thesis of a considerable 
reduction of the required dose and of the ASO-induced toxicity. 
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The approach of CPP-MO oligomers has been successfully used to 
treat other kind of diseases and even viral or bacterial infections [129]. 
In particular, it has been improved the capacity of ASO to inhibit viral 
replication in vivo by blocking the transcription of viral genome [130-
134]. As a matter of fact, to treat bacterial infections, different MOs with 
antimicrobial activity have been coupled with CPPs [135-138]. The 
advantages of this technique is the possibility to decrease the dosage 
of many antibiotics, and probably the toxicity of many of them, and the 
increase of bacterial membrane permeability to several antibacterial 
compounds. 
The conjugation of MOs with CPPs can occur either via covalent or 
non-covalent bonding [139, 140]. The strategy of covalent conjugation 
seems to be better because it is very reproducible and it allows to 
obtain a precise stoichiometry of the synthetized construct, while the 
synthesis of non-covalent complexes may alter the biological activity of 
the associates cargos. 
1.5.6 PROTEIN DELIVERY 
Another class of molecules that can be used as therapy in many 
diseases is represented by proteins. But there are a lot of issues linked 
to their use. First of all, in order to preserve their biological activity, they 
have to maintain their tertiary or quaternary structure. The final 
structure is guaranteed by weak and non-covalent bonds between 
amino acids residues and this is the reason of short half-life, poor 
penetration across biological membranes and low stability of proteins in 
biological fluids and tissues. 
To overcome this problem, it has been tested the use of CPPs to 
deliver therapeutic proteins in vivo. Several proteins such as human 
catalase, human glutamate dehydrogenase [141], Bcl-xL [142], Cu/Zn 
SOD [143], heat shock protein 70 [144], the Nf-kB inhibitor srIkBa [145], 
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eGFP [146] are some examples of how this strategy has been 
successfully employed.  
The CPPs-protein conjugates can be synthesized using a covalent or 
non-covalent bonding [147, 148], as previously reported for siRNAs, 
oligonucleotides and DNAs, or it is possible to generate a single 
chimeric protein without the need of additional modification. 
 
1.6 CLINICAL TRIALS 
Ended before completion date, the first Phase II clinical trial was based 
on the use of CPP-cargo in humans and was conducted in 2003 as a 
treatment for psoriatic lesions (PsorBan by CellGate Inc.).  
Another Phase II clinical study, completed in 2010 (NCT00451256), 
was named AVI-5126. The aim of the CPP-MO conjugate was the 
reduction of the occurrence of coronary artery restenosis by inhibition 
of c-myc. This trial was sponsored by Sarepta Therapeutics, which is 
also developing other conjugates. One of these is AVI-5038, an 
(RXRRBR)2 XB-MO construct used to treat Duchenne Muscular 
Dystrophy [149]. The mechanism of action of this compound is the 
exon 51 skipping in the dystrophin gene, inducing the expression of a 
shorter but functional dystrophin protein. Even if AVI-5038 is under 
preclinical evaluation, it has been expected to be enter clinical practice 
soon as an unconjugated MO oligonucleotide AVI-4658 (called 
Eteplirsen)10. 
In order to reduce the area of myocardial damage after acute 
myocardial infarction, the drug KAI-9083 has been tested in a human 
Phase II clinical trial 11. It is a conjugate of the selective inhibitor of the 
                                                          
10Source:http://investorrelations.sarepta.com/phoenix.zhtml?c=64231&p=irolnewsArticl
e&ID=2204492 
11 Registered on ClinicalTrials.gov, Identifier: NCT 00785954 
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d-Protein Kinase C (d-PKC) with the TAT peptide. The trial ended in 
2011 and didn’t demonstrate the efficacy of the compound. However, 
the trial proved the safety of the compound also in humans. 
Another drug, similar to KAI-1678, a g-PKC-TAT conjugate, have been 
used to reduce the pain in spinal cord injured patients. It has been 
tested in a Phase II clinical trial 12 which ended in 2011 with no better 
results than placebo. 
In 2016, a Phase II clinical trial investigated the safety and efficacy of 
RT-001 as treatment for Primary Axillary Hyperhidrosis13. This molecule 
comprises the Botulinum toxin type A conjugated with two TAT 
moieties, and was formulated as a topic gel. The identical molecule 
was used in a Phase III clinical trial 14 for the treatment of moderate to 
severe lateral canthal lines. The trial was completed in September 
2016, the data of this trial are not currently available. 
All these clinical studies proved the safety of CPP-drugs but they show 
that additional developments of CPPs chemistry and efficacy could 
have a significant positive impact on human pharmacology in the next 
years. 
 
                                                                                                                                            
 
12 Registered on ClinicalTrials.gov, Identifier: NCT 01135108 
13 Registered on ClinicalTrials.gov, Identifier: NCT 02655732 
14 Registered on ClinicalTrials.gov, Identifier: NCT 02580370 
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2. AIM OF THE STUDY 
To date, Spinal Muscular Atrophy (SMA) is the first cause of infant 
mortality among neuromuscular disorders. It is caused by a 
homozygous mutation in the SMN1 gene, which produces a non-
functional SMN protein. From a clinical point of view, the affected 
patients are classified into 5 forms of SMA, from the most severe form 
(SMA 0) to the mildest one (SMA IV). This phenotypic heterogeneity is 
mainly due to the presence, in the human genome, of a paralogous 
gene, SMN2. A single nucleotide substitution in the SMN2 gene leads 
to the skipping of the exon 7 in the vast majority of the mRNA and the 
production of a truncated or unstable SMN protein for a 90%, and of a 
full-length SMN protein for a 10%. The severity of the pathology is 
inversely related to the number of SMN2 copies in the genome. 
One possible therapeutic strategy for SMA is the modulation of the 
alternative splicing of the mRNA on the SMN2 gene, promoting the 
inclusion of the exon 7 and the expression of a full length functional 
SMN protein. 
To date, the only approved therapy for SMA is the use of an Antisense 
Oligonucleotide (ASO), Nusinersen, which binds a specific region on 
SMN2, called ISS-N1, and block sterically the gathering of the splicing 
machinery that causes exon 7 skipping. ASOs with different chemistry 
have been already studied in animal models and in patients. In 2014, 
our group tested a particular ASO, called Morpholino, which targeted 
the 10-34 region of the ISS-N1 of the SMN2 intron 7 (MO-10-34). Our 
data showed that if MO-10-34 was administered at birth, the life 
expectancy and the neuromuscular function strikingly improved in the 
transgenic model of SMA [83].  
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It has been proved that the use of different sequences within and 
adjacent to ISS-N1 causes different therapeutic effects [83] and so the 
refinement of the target sequence could be a promising tool to obtain a 
better therapeutic effect. Additionally, a combined administration of 
multiple ASO oligomers has never been evaluated in detail. For all 
these reasons we decided to test new MO sequences using also a 
combined administration of them to improve the splice-correction effect 
of a single sequence. 
One of the pitfalls of ASOs therapy is the need of a relative invasive 
administration into the cerebrospinal fluid (CSF) by lumbar puncture to 
reach the central nervous system (CNS). To solve this problem, 
different delivery strategies have been explored. One of these is the 
use of cell-penetrating peptides (CPPs), such as short peptide 
sequences of 5-40 amino acids that can pass through biological 
membranes. Due to their good efficacy and low toxicity in vivo, CPPs 
are often used as biological carriers. When they are linked to an ASO, 
they can improve its pharmacokinetic properties and bio-distribution, 
supporting the chance of their application in clinic. 
We proposed to test if the conjugation of our validate MO sequence to 
different CPPs could increase the distribution and the delivery of MO in 
the CNS. We also compared two different administrations, the local and 
the systemic one, in a murine SMA model, in order to determine the 
most efficient CPP. 
To summarize, the specific aims of this study are: 
• the validation of new MO sequences alone or in combination in our 
in vitro and in vivo SMA models; 
• the evaluation of the conjugates CPPs-MO in terms of: 
o ability to cross the Blood Brain Barrier (BBB) after systemic 
administration 
40 
 
o capacity to increase tissue distribution in brain and spinal 
cord 
o opportunity of expanding the therapeutic window, allowing 
the treatment of SMA mice in a symptomatic phase. 
This study will prove the possibility to use a CPP as a biological carrier 
for ASOs, allowing a systemic, non-invasive administration of the best 
conjugate. We expect to optimize our results in a preclinical context 
and to translate them in clinical trials and in clinical practice for the 
patients. 
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3. MATERIALS AND METHODS 
3.1 PHOSPHORODIAMIDATE MORPHOLINO 
OLIGONUCLEOTIDES 
The sequences of MO investigated in this study are designed to refine 
a 15 nucleotides inhibitory sequence downstream of the 5’ splicing site 
in the intron 7 of the SMN2 gene. This element is identified as intronic 
splicing silencer N1 (ISS-N1) as previously described. Oligonucleotide 
nomenclature identifies the intronic annealing coordinates, thus MO (-
10-34) refers to a molecule annealing between bases 10 and 34 from 
the beginning of SMN2 intron 7. 
The list of tested MOs is here provided: 
 
o MO-10-34:GTAAGATTCACTTTCATAATGCTGG 
o MO-Scr: GTAACATTGACTTTGATATTCCTGG 
o MO-A:TCATAATGCTGGCAGAC 
o MO-B: GTAAGATTCACTTTCATAATGC 
o MO-C: GATTCACTGTCAGAAGGCTGGCAGAC 
o MO-D: GATTCACTCTCACAACGCTGGCAGAC 
 
All MO oligomers were manufactured by Gene Tools (Philomath, USA) 
with a protocol previously reported [139] and have been designed 
taking into account analysis by bioinformatic tools to target ISSN-1.The 
previously validated MO-10-34[83] was used as reference sequence 
and the scr-MO was used as negative control sequence. 
The novel MO oligomers (MO-A, B, C, D) were synthesized to match 
the region downstream of exon 7; in particular, MO-A and MO-B 
precisely matched the intronic ISSN-1 motif of the SMN2 gene, while 
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only the first 10 nucleotides of MO-C and MO-D perfectly 
complementary bound to the ISSN1 intronic motif. 
All the sequences were resuspended in sterile saline (0.9% sodium 
chloride) solution at the appropriate concentration for injection. 
 
3.2 CONTROL CELL LINE 
We used Hela cells as human immortalized wild-type line. The culture 
medium for this line was Dulbecco’s modified Eagle’s medium 
(MEM)/F12, with 15% Fetal Bovine Serum, 1% pen/strep, 1% 
amphotericin B (Life Technologies).1.5X 104cells were cultured into 24-
well and subsequently maintained for 24 hours prior to transfection. 
 
3.3 REPROGRAMMING OF HUMAN SOMATIC CELLS 
INTO IPSC 
We reprogrammed SMA type 1 and wild-type skin fibroblasts into 
induced pluripotent stem cells (iPSCs) (n=3 per condition). The 
reprogramming has been performed using a non-integrating viral 
method, based on the CytoTune®-iPS 2.0 Sendai Reprogramming Kit 
(Life Technologies). The non-integrating Sendai virus (SeV) has been 
used to carry the 4 transcription factors described by Yamanaka at al. 
[150]: Oct4, Sox2, Klf4 and c-Myc. The reprogramming rate is 
guaranteed by the expression efficiency of these 4 transcriptional 
factors. 
The first step of the reprogramming method consisted in culturing the 
SMA fibroblasts in DMEM high glucose (Life Technologies) 
supplemented with 15% fetal bovine serum (FBS) (Euroclone) and 
antibiotics until 50 to 80% confluence. The viral vectors (KOS, hc-Myc 
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and hKlf4) with the appropriate MOI (respectively: MOI=5-5-3) were 
added. 
24h after the treatment, the medium was changed in order to eliminate 
the residual reprogramming vectors. 
After 5 days, reprogrammed cells were detached and transferred in 
plates pre-coated with a layer of human embryonic fibroblasts (ATCC). 
At day 8, the medium was substituted with a specific medium for iPSCs 
(Essential 8 Medium, Life Technologies). 
After 9 days, cells have been monitored for morphological changes 
towards iPSCs colonies, that usually were detected between two and 
four weeks after transduction. Then, colonies were isolated and grown 
in Essential 8 Medium. For the first passages, cells were grown on 
fibroblasts layer. Gradually, iPSCs colonies were transferred into plates 
pre-coated with a thin layer of cultrex (Cultrex® Stem Cell Qualified 
Reduced Growth Factor Basement Membrane Extract Path Clear; 
Thema Ricerca), which is needed for their proper adhesion. 
 
3.4 DIFFERENTIATION OF IPSCS INTO MOTOR 
NEURONS 
We differentiated MNs applying a multistep differentiation method 
implemented for pluripotent stem cells [152]. To obtain MNs, we 
seeded iPSCs with neuronal medium [DMEM/F12 (Gibco, Invitrogen), 
with MEM nonessential amino acids, N2, and heparin (2 μg/mL, Sigma-
Aldrich)]. To determine neural caudalization, we supplemented the 
medium with retinoic acid (RA) (0.1 μM, Sigma-Aldrich) after 10 days. 
At day 17, we collected the posteriorized neuroectodermal cells. These 
cells aggregates were resuspended for 1 week in the same medium 
with RA (0.1 μM) and sonic hedgehog (SHH) (100–200 ng/mL, R&D 
Systems Inc.). On day 24, we supplemented the medium with 
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additional growth and neuroprotective substances [e.g., brain-derived 
neurotrophic factor (BDNF), glial-derived neurotrophic factor (GDNF), 
and insulin-like growth factor-1 (IGF1) (10 ng/mL, Peprotech). To select 
MNs we used a gradient centrifugation protocol. 
 
3.5 MORPHOLINO TRANSFECTION 
To promote transfection efficiency, nucleofection was undertaken with 
the Neon Nucleofection System (Life Technologies) following the 
manufacturer guidelines. Briefly, cells Hela cells and SMA iPSCs were 
detached, counted and centrifuged. The cell pellet was resuspended in 
100μl of Resuspension Buffer (Life Technologies).  
Twenty micrograms MO were added to the cells and mixed by 
vortexing. Since MO-B and MO-D were the most efficient sequences, 
we employed a combination of these two oligomers, using the same 
total dose (10 μg MO-B + 10 μg MO-D). 
Each sample was transferred with the Neon TM Pipette to a 
nucleofection cuvette and nucleofected using the proper set pulse 
condition. After nucleofection, the cells were then transferred on the 
culture plate previously prepared with pre-warmed culture medium. 
Transfected HeLa cells were collected 72h after treatment for 
immunocytochemical and western blot analyses. Treated SMA iPSCs 
and MNs were collected at different time frames: 72h, 7 days and 21 
days after nucleofection. 
To promote the transfection of MNs, we used the endo-porter kit (Gene 
Tools), following the manufacturer guidelines. Briefly, we started from 
plated MNs with a confluence of 60-80%. We replaced culture medium 
with fresh complete medium (containing up to 10% serum). We added 
a combination of two oligomers (10 μg MO-B + 10 μg MO-D) to the 
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medium and 6 μl of Endo-porter for every 1ml media and immediately 
swirl to mix (the final Endo-porter concentration should be of 6 μM). 
The nucleofected MNs were collected 72h after the treatment for 
immunocytochemical analysis. 
 
3.6 IMMUNOCYTOCHEMISTRY 
3.6.1 IPSCs CHARACTERIZATION 
Immunocytochemistry for pluripotency markers was performed on 
iPSCs. Cells were fixed in 4% paraformaldehyde for 10 minutes, 
permeabilized with 10% BSA and 0.3% TritonX-100 in phosphate-
buffered saline solution (PBS) for 1 hour at room temperature. Cells 
were exposed overnight at 4°C to primary antibodies (SOX2, OCT4, 
NANOG mouse monoclonal, Chemicon, 1:500; SSEA3, SSEA4, mouse 
monoclonal, Chemicon, 1:500, TRA1-60, TRA1-81 mouse monoclonal, 
Chemicon, 1:500; anti- SMN, 1:100, BD). The day after the cells were 
washed 3 times with PBS solution to remove the excess of 
unconjugated antibodies, and then incubated for 1 hour and 30 minutes 
at room temperature with secondary antibodies conjugated with the 
fluorophores Alexa Fluor 488 or 568 (anti-mouse antibody, 1:1000, 
Invitrogen) for pluripotency markers or with the secondary anti- mouse 
FITC-conjugated antibody (1:100, Dako). Nuclei were stained with 
DAPI. Images were acquired using the LEICA LCS2 confocal 
microscope. Results are expressed as mean ± s.e.m. for five 
independent experiments. 
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3.6.2 GEMS QUANTIFICATION 
The SMN expression level was determined in Hela cells and in SMA 
iPSCs also evaluating by immunocytochemistry the presence of 
aggregates of SMN called “gems”. The cells were grown on slides were 
washed with PBS and fixed with 1:1 acetone:methanol for 5 min. 
Subsequently, they were incubated with a solution of 10%BSA, 
2%Triton in PBS. Then, after washing cells were incubated with an 
antibody against SMN in 3% BSA overnight at 4 degrees (1:100, BD). 
Cells were washed with PBS and exposed for 1 hour to secondary 
antibodies (Alexa Fluor, Invitrogen). After washes with PBS, the cells 
were then incubated with DAPI (Invitrogen). 
The number of gems was quantified following the protocol reported in a 
previous study [151]. Cells were examined with an SP2 AOBS confocal 
microscope. Two independent investigators examined at least 100 cells 
in randomly selected fields from each slide and recorded the gems 
number and the percent of cells with gem-positive nuclei in the different 
treatments. 
 
3.6.3 MOTOR NEURON PHENOTYPIC ANALYSIS 
We evaluated the MN phenotype by morphological and 
immunohistochemical analysis. We used the following antibodies: TuJ1 
(1:200, Millipore), OLIG2, (1:500, Santa Cruz), ISLET1 (1:200, 
Millipore), HB9 (1:200 Millipore), ChAT (1:200, Millipore), MAP2 (1:100; 
Sigma), and SMI32 (Covance, 1:500). The method is described in 
detailed above for iPSC staining. For phenotypic analysis, the 
percentage of positivity in a sample was obtained by averaging 
proportions of a specific cell type in each of 10 randomly chosen fields. 
Five independent experiments in triplicate were performed. 
Morphometric and MN count analysis were carried out as previously 
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described by us. Results are expressed as mean ± s.e.m. for five 
independent experiments. 
 
3.7 CONJUGATION OF MOs TO CELL PENETRATING 
PEPTIDES 
The peptides we chose to be conjugated with MO were the following 
(Figure 9): 
- HIV1 TAT peptide (sequence: YGRKKRRQRRRQ), 
- two polyarginine peptides (namely R6 and r6, sequence RRRRRR). 
The two peptides are made up by six arginine with a L (R6) or D (r6) 
enantiomeric configuration. 
- (RXRRBR)2 XB peptide (namely RXR). 
All the peptides were synthetized by the commercial peptide supplier 
Peptide 2.0. All CPPs were conjugated to the previously validated MO 
sequence (MO-10-34) [83], synthetized by Gene Tools, LLC. Each 
peptide have been linked to the 5’ end of the MO through non-
cleavable maleimide bond as reported [153]. The conjugation process 
was performed by our external collaborator Hong Moulton (University of 
Oregon) using a method already described [154, 155]. The lyophilized 
compounds were dissolved in sterile saline solution to obtain the final 
correct concentration. 
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Figure 9: Cell Penetrating Peptides tested in this study 
 
3.8 SMA TRANSGENIC MICE 
All the transgenic animals were purchased from The Jackson 
Laboratory (Figure 10). All animal experiments were approved by the 
University of Milan and Italian Ministry of Health review boards, in 
compliance with US National Institutes of Health Guidelines [53]. 
We employed the transgenic mouse model usually identified as 
SMA∆7 (SMN2+/+; Smn-/−; SMNΔ7+/+). This triple mutant mouse 
harbors two transgenic alleles and a single targeted mutant. The 
Tg(SMN2*delta7)4299Ahmb allele is a SMA cDNA lacking exon 7 
while the Tg(SMN2)89Ahmb allele is the entire human SMN2 gene.  
Animals that are homozygous for the knockout Smn allele and 
homozygous for the two transgenic alleles show signs/symptoms and 
neuropathology that mimic SMA type 1. At birth, triple mutants are 
smaller than wild-type littermates. By P5, signs of muscle weakness 
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are evident and become progressively more severe over the following 
week. The mice cannot stand or walk on their limbs. Mean survival is 
approximately 13 days.  
 
 
 
 
 
Figure 10: Genetically engineered and mutant mice from the Jackson Laboratory: gene 
and allele information (http://jaxmice.jax.org/strain/007952.html). 
Non affected heterozygous male and female (SMN2+/+; Smn+/−; 
SMNΔ7+/+) were bred and pups were identified by genotyping as 
described below. 
 
3.9 MOUSE GENOTYPING 
2 mm of tail tissue from SMA pups was cut and collected into an 
Eppendorf tube. 
For the DNA extraction, 100 µL of 50 mM NaOH were additioned to 
each sample and each tube was located in the water bath at 95ºC for 
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10 minutes. 25 µL of 1M TrisHCl pH 8.0 solution were then added to 
each sample. Then, samples were mixed by vortexing. After the DNA 
extraction, it was amplified carrying out a standard PCR with 35 cycles. 
The conditions and the primers sequences are here presented: 
 
• Primer 
sequences: 
RIMER 
PRIMER TYPE SEQUENCE 5’ TO 3’ 
oIMR3679 Transgene TCCATTTCCTTCTGGACCAC 
oIMR3680 Transgene ACCCATTCCACTTCCTTTTT 
oIMR8744 Internal Positive 
Control Forward 
CAAATGTTGCTTGTCTGGTG 
oIMR8745 Internal Positive 
Control Reverse 
GTCAGTCGAGTGCACAGTTT 
 
 
• PCR: components and cycling 
REACTION COMPONENT 
VOLUME 
(µL) 
FINAL 
CONCENTRATION 
ddH2O  3.56 - 
10X AB PCR BufferII 1.20 1-00 x 
25 mM MgCl2 0.96 2.00mM 
2.5 mM dNTP 0.96 0.20mM 
20 µM oIMR3679 0.60 1.00 µM 
20 µM oIMR3680 0.60 1.00 µM 
20 µM oIMR8744 0.20 0.33 µM 
20 µM oIMR8745 0.20 0.33 µM 
5 Mm DNA loading Dye 1.66 0.69 µM 
5 U/µL Taq DNA Polymerase 0.06 0.03 U/µL 
DNA sample 1.50 - 
 
• Separation of PCR products by gel electrophoresis on a 1.5% 
agarose gel. 
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3.10 MORPHOLINO ADMINISTRATION IN SMA MICE 
The most efficient MOs in vitro were tested in vivo in heterozygous 
SMA mice (genotype: Smn+/-, hSMN2+/+, SMNΔ7+/+) to confirm the 
increase of SMN protein levels (Table 3). 
The MOs tested were MO-B, MO-D and MO-B + MO-D. At post-natal 
day 1 (P1), the different MO solutions were administered 
intracerobroventricularly (ICV) and subcutaneously (SC)at a dosage of 
12 nmoles for each injection in heterozygous pups. At P3 extra 12 
nmoles were injected SC. The same dose was used for the combined 
delivery of MO-B + MO-D, 6 nmoles MO-B plus 6 nmoles MO-D for 
each injection. 
The volume of each injection was 2.4µL. Treated mice were sacrificed 
at P7 and brain and spinal cord were collected for further 
neuropathological and proteomic analyses. 
MOs were suspended in sterile saline, and mixed with Evans Blue (final 
concentration 0.04%) and stored at −20°C. 
The ICV injection was performed as previously described [83] cryo-
anesthetized mice were hand-mounted over a back-light to visualize 
the intersection of the coronal and sagittal cranial sutures (bregma).A 
fine-drawn capillary needle with injection assembly was then inserted 1 
mm lateral and 1 mm posterior to bregma and then tunnelled 
approximately 1 mm deep from the skin edge, corresponding to the 
ipsilateral lateral ventricle. An opaque tracer (Evans Blue, final 
concentration 0.04%) was mixed to the reagent so that the borders of 
the lateral ventricle could be visualized after the administration of the 
MOs.SC injections were performed as previously described by Hua 
team [74]. 
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Treatment 
group 
n 
Mice 
genotype 
Treatment Dosage 
Route and time of 
administration 
Control group 3 Hetero SCr-MO 12 nmol/g 
ICV + SC at P1 and 
SC at P3 
1 3 Hetero MO B 12 nmol/g 
ICV + SC at P1 and 
SC at P3 
2 3 Hetero MO D 12 nmol/g 
ICV + SC at P1 and 
SC at P3 
3 3 Hetero MO B +MO D 
6 nmol/g 
MO B+6 
noml/g MO 
D 
ICV + SC at P1 and 
SC at P3 
4 3 Hetero MO 10-34 12 nmol/g 
ICV + SC at P1 and 
SC at P3 
 
Table 3: Description of treatment groups. Treatment dose is referred as dose/ injection. 
Abbreviations: scr, scrambled; nmol, Nano Moles; ICV, intracerebroventricular injection; 
SC, subcutaneous injection; P, post-natalday; Heterozygous mice genotype: Smn+/-
,SMN2+/+, SMN∆7+/+. 
 
3.11 DELIVERY OF CPP-MO COMPOUNDS 
Different groups of animals were treated with CPP-MO conjugates. 
First, we treated affected symptomatic homozygous mice with TAT-MO 
in comparison to unconjugated MO-10-34. In particular, the first group 
of homozygous mice (n=9) received a low dose of TAT-MO (6 
nmoles/g) ICV plus a 6nmoles/g SC at P5 and an extra 6nmoles/g TAT-
MO SC at P7.A second group (n=14) of homozygous mice received a 
high dose of TA-MO (12nmol/g per injection)  ICV plus SC at P5 and an 
extra SC injection at P7.The two groups of treated mice were compared 
to two control homozygous groups treated with unconjugated MO 10-34 
at low dose (6 nmoles/g, n=10 treated mice) and high dose (12 
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nmoles/g, n=9 treated mice) following the same administration scheme 
(Table 4). 
ICV and SC injection are already described in the previous section 
(3.10). Survival of the treated mice was monitored. 
 
Treatment 
Group 
n Treatment dosage 
Administration 
route and time of 
treatment 
Mean 
survival 
High dose 
group 
14 
TAT-MO-10-
34 
12 
nmol/g 
ICV+SC at P5 plus 
SC at P7 
47,14 d 
Low dose 
group 
9 
TAT-MO-10-
34 
6 nmol/g 
ICV+SC at P5 plus 
SC at P7 
27,777 d 
Control group 10 
Unconjugated 
MO-10-34 
6 nmol/g 
ICV+SC at P5 plus 
SC at P7 
25,2 d 
Control group 9 
Unconjugated 
MO-10-34 
12 
nmol/g 
ICV+SC at P5 plus 
SC at P7 
41 d 
 
Table 4: Comparison between homozygous mice treated with TAT-MO and MO-10-34. 
Dose is referred as dose/injection. Abbreviations: d, days; nmol, NanoMoles; ICV, 
intracerebroventricular injection; SC, subcutaneous delivery. 
 
In parallel, small pilot groups of non-affected heterozygous animals 
(Smn+/-, SMN2 +/+, SMNΔ7+/+) were injected with MO-(10-34) linked 
with one of the four different CPPs: TAT, R6, r6, RXR (Table 5). In this 
case, we used two routes of administration. We injected ICV plus SC 
with 2.4 µL/g of CPP-MO per injection, which corresponds to 
12nmoles/g, at P1 and an extra dose SC at P3. Other pilot groups were 
treated intravenously (IV) into the facial vein with 12 nmoles/g of each 
CPP-MOs, which were further diluted to a final volume of 50 µL. The 
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same two protocols were applied for the delivery of unconjugated MO-
(10-34) as positive control [156]. 
Treated mice were sacrificed at P7. The brain and the spinal cord were 
collected for further neuropathological and proteomic analyses. 
 
Treatment 
Group 
n Treatment dosage 
Administration 
route and time of 
treatment 
Mean 
survival 
TAT group 1 1 TAT-MO-10-34 12 nmol/g 
ICV+SC at P1 plus 
SC at P3 
Sacrificed 
at P7 
R6 group 1 1 R6-MO-10-34 12 nmol/g 
ICV+SC at P1 plus 
SC at P3 
Sacrificed 
at P7 
r6 group 1 1 r6-MO-10-34 12 nmol/g 
ICV+SC at P1 plus 
SC at P3 
Sacrificed at 
P7 
RXR group 1 1 
(RXRRBR)2XB-
MO-10-34 
12 nmol/g 
ICV+SC at P1 plus 
SC at P3 
Sacrificed 
at P7 
TAT group 2 1 TAT-MO-10-34 12 nmol/g IV at P1 
Sacrificed 
at P7 
R6 group 2 1 R6-MO-10-34 12 nmol/g IV at P1 
Sacrificed at 
P7 
r6 group 2 1 r6-MO-10-34 12 nmol/g IV at P1 
Sacrificed 
at P7 
RXR group 2 1 
(RXRRBR)2XB-
MO-10-34 
12 nmol/g IV at P1 
Sacrificed 
at P7 
 
Table 5: CPPs-MO treatments in heterozygous mice. Dose is referred as 
dose/injection. Abbreviations: d, days; nmol, NanoMoles; ICV, intracerebroventricular; 
injection; SC, subcutaneous injection; IV, intravenous injection. Homozygous genotype: 
Smn-/-, SMN2+/+, SMN∆7+/+; Heterozygous genotype: Smn+/-, SMN2+/+, SMN∆7+/+. 
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The experiment for the evaluation of the efficacy of the conjugates on 
survival, neuromuscular function and neuropathological phenotype on 
symptomatic affected SMA mice are ongoing. 
 
3.12 WESTERN BLOT ASSAY 
Cells were washed with PBS solution and detached by mechanical 
scraping. Lysis buffer additioned with protease and phosphatases 
inhibitors mix (Pierce) was then added and the cells were lysed by 
sonication for 10 s on ice to avoid overheating. The lysates were then 
centrifuged at 13,500 rpm for 10 min at 4°C.  
Twenty milligrams of frozen tissue were homogenized in 0.4 mL (brain) 
or 0.2 mL (spinal cord) of 1× protein sample buffer containing 2% 
(wt/vol) SDS, 10% (vol/vol) glycerol, 50 mM Tris hydrochloride (pH 6.8), 
and 0.1 M dithiothreitol. Protein concentration was determined by 
Pierce Comassie Plus Protein Assay (an improved Bradford assay, 
Pierce). 
Twenty micrograms of proteins were separated by electrophoresis 
using 12% SDS-PAGE and then electrophoretically transferred onto 
nitrocellulose membranes. Membranes were incubated with 1%BSA, 
10% horse serum, 0,075% Tween 20 in TBS (20 mM Tris-HCl, 0.5 M 
NaCl) solution for 1 hour at room temperature (RT) to prevent any non-
specific binding of antibodies. The membrane was then exposed 
overnight at 4°C to the primary antibody resuspended in saturating 
solution: anti-human SMN (1:15,000, amino acids 14–174, BD 
Biosciences) or anti-β-actin (1:250, Sigma) as a reference loading 
protein. After three washings of 15 minutes with TBS-T solution (20 mM 
Tris- HCl, 0.5 M NaCl, 0.05% Tween 20), the membranes were probed 
with secondary peroxidase-conjugated antibody (Invitrogen) 
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resuspended in saturating solution. After three washing with TBS-T, 
immune complexes were detected using chemiluminescent detection 
system (ECL solution, Amersham). Densitometric analysis was 
performed using Image J software. 
 
3.13 BEHAVIORAL TESTS 
The experiment for the evaluation of the efficacy of the conjugates on 
survival, neuromuscular function and neuropathological phenotype on 
symptomatic affected SMA mice are ongoing. All treated mice were 
monitored every day for morbidity, mortality and changes in weight by 
investigators that were blind to the treatment. Body weight was 
measured daily using a standard small animal balance. The mice were 
sacrificed at the clinical end point when they presented difficulties in 
feeding, a clear downward trend (mice with 30% weight loss and 
severe paralysis), and breathing problems.  
Behavioral tests were carried out as previously reported [53, 74]. In 
particular, the neuromuscular function of treated mice was evaluated by 
the rotarod test, righting reflex assay and hind-limb suspension test 
(also referred as Tube Test).  
The rotarod test comprises 4 phases of acceleration (4–40 rpm, 
maximum time 5’; Rota-Rod 7650; Ugo Basile). The length of time that 
each mouse remained on the rotarod the portion of no-fall tests were 
recorded. 
Hind-limb suspension and righting reflex tests were performed as 
previously described [54, 157]. 
The righting reflex is employed to determine motor function of mice at 
early developmental ages. It defines the capacity of the mouse to 
perform the necessary movement to roll over from its back onto its 
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paws. Incapacity to right, or significant delays in righting point out 
defects in motor functioning. The test was assessed starting from P2. 
For this test, each mouse was placed on its back on a flat surface in a 
supine position, Its success or failure to stably reposition on all four 
paws on the ground was assessed over a 30 s period (cut off time of 60 
s)[60]. 
The hind-limb suspension test (HLST, a.k.a. the tube test) is designed 
for the evaluation of proximal hind limb muscles, weakness and fatigue 
in early stage of mouse development. It assesses also general 
neuromuscular function. The test is generally performed in 2 
consecutive trials.  
The mouse is placed head-down and hanging by its hind limbs from the 
edge of a standard 50 ml plastic centrifuge tube with a cotton ball 
cushion at the bottom to protect the animal's head upon its fall. The 
HLST results are expressed by the latency time to fall from the edge of 
the plastic tube and by the Hind-limb Score (HLS). 
The HLS evaluates the positioning of the legs and tail. Based on the 
posture of mice. These scores are assigned following the criteria 
presented in a previous study [158]: 
• score 4: indicates normal hind-limb separation with tail raised; 
• score 3: weakness is evident and hind limbs are closer together but 
they seldom touch each other; 
• score 2: hind limbs are close to each other and often touching; 
• score 1: weakness is evident and hind limbs are almost always in a 
clasp position with the tail raised; 
• score of 0: indicates constant clasping of the hind limbs with the tail 
lowered. 
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HLS scores are determined during the first 10 to 15 s of hanging from 
the plastic tube. In case the pups failed to hold onto the tube, an HLS 
score of 1 was given.  
 
3.14 STATISTICAL ANALYSIS 
We used Prism software for statistical analyses. All quantification data 
from immunocytochemical analyses and cell survival were expressed 
as mean values ± S.D or s.e.m. Differences between two means were 
analyzed using Student’s t-test (two-tailed), and differences among 
more than two means were evaluated by one- or two-way ANOVA. 
When ANOVA showed significant differences, pair-wise comparisons 
between means was carried out using Tukey’s post-hoc test. For the 
survival curve analysis, data are expressed as means plus standard 
errors. Kaplan–Meier curves were obtained from the survival data and 
evaluated by the Mantel–Cox log-rank test. In all tests, the null 
hypothesis was rejected when p was less than 0.05. 
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4. RESULTS 
4.1 SMN UPREGULATION IN HUMAN WILD-TYPE CELLS 
USING NOVEL MO SEQUENCES 
Our group have already validated a 25 nucleotides MO sequence to 
targeting the intronic splicing motif referred as ISS-N1 in the human 
SMN2 gene [83]. This MO oligomer was identified as 
HSMN2Ex7D(10,34), or MO-(10-34), due to its ability to pair the exon 7 
donor site. 
Our group demonstrated the efficacy of this sequence in promoting 
exon 7 inclusion in the SMN2 mRNA and in upregulating the levels of 
the functional full length isoform of the SMN protein both in vitro and in 
vivo [83]. 
We decided to compare the already tested efficacy of MO-(10-34) 
oligomer with four newly designed MO sequences (MO A, B, C, D), all 
tailored to bind the ISS-N1 region downstream of SMN2 exon 7. In 
particular, while MO-A and B oligomers precisely overlap the target 
intronic splicing site of the SMN 2 gene, MO-C and MO-D sequences 
match only for the first 10 nucleotides the ISS-N1 splicing site.  
MO novel sequences were produced by Gene Tools by an already 
described method of synthesis [159]. As negative control we used a 
scrambled MO sequence (scr-MO) that was designed using 
bioinformatics software tool to predict the most appropriate control 
sequence (Gene Tools, www.genetools.com). 
The novel MO sequences and their positive/negative controls were 
tested in a human immortalized wild-type cell line, Hela cells. Cells 
were nucleofected with 20µg of the four MO oligomers or the scr-MO 
control sequence following the protocol described in manufacturer 
instructions. 
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Cells were collected72h after MO nucleofection for western blot and 
immunocytochemical to measure SMN levels. 
Data obtained from western blot proved that all the four sequences are 
able to increase in the SMN protein levels compared to the scramble 
treated cells, and in particular MO-B and MO-D presented the highest 
activity among the newly designed oligomers (Figure 11). For this 
reason, we decided to combine the administration of MO B and MO D 
in order to verify the possible additive effect of the two compounds. The 
protein analysis revealed that the combination of these two MOs 
produced a greater effect than the two oligomers alone and it was 
similar to that obtained with MO-10-34 that serves as positive control 
(p< 0.05, Figure 11).  
 
 
 
 
Morpholinos 
 A        B        C      D       B+D    MO
10-34
 
   ctrl 
SMN 
Actin 
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Figure 11: Western blot (upper panel) and densitometric analysis (lower panel) of wild-
type HeLa cells treated with different MO sequences and scr-MO as negative control. 
 
Another evaluated parameter was the presence of nuclear complexes, 
named gems. These structures are detectable only when SMN protein 
is present and are critical for the correct processing of RNA 
messengers. The gems number was quantified and expressed as the 
mean value of the ratio between the number of gems counted and the 
number of nuclei present in each examined area. 
The immunocytochemical analysis (Figure 12) revealed that MO-B, D, 
B+D and MO-(10-34) were able to significantly up-regulate the number 
of gems in particular the gems/nuclei ratio respect to scr-MO treated 
controls (p<0.05, Figure 12). No significant upregulation was detected 
in the presence of MO-A or MO-C. Moreover, the most significant up-
regulation in the gems and in the gems/nuclei ratio was determined 
after the co-administration of MO-B + MO-D (mean ratio = 0.71), as 
already shown by western blot analysis. These results were statistically 
significant as demonstrated by one-way ANOVA and post-hoc Tukey’s 
test (p=0.0048) (Figure 13). 
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Figure 12: Immunocytochemical analysis of treated wild-type HeLa cells with MOs. 
Nuclear gems (green) were observed in the nucleus of all treated cells and the greatest 
increase in their number was detected after the co-treatment with MO-B + MO-D. 
Nuclei are stained with DAPI 
 
 
 
Figure 13: Analysis of the means of gems/nuclei ratio in wild-type HeLa cells after 
exposure with different MO sequences. The greatest increase was observed after the 
co-treatment with MO B + MO D 
 
4.2 MO NOVEL SEQUENCES UP-REGULATE SMN 
PROTEIN IN SMA iPSCs 
To obtain a suitable SMA in vitro model, we reprogrammed patients 
(SMA type 1) and wild-type skin fibroblasts in iPSCs (n = 3 per 
condition). For this purpose, we used a non-integrating viral approach 
based on the use of Sendai Virus, to efficiently transfer the required 
stem transcription factors (OCT4, SOX2, KLF4 and c_Myc, OSKM) 
described by Yamanaka et al.[150]. After the reprogramming iPSCs 
colonies with typical ES-like morphology appeared in culture and were 
manually isolated. The cells showed the characteristics 
nuclear/cytoplasm ratio and are pluripotent since they can originate 
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embryoid bodies with the three germ layers. The iPSC correctly 
expressed the pluripotency markers SOX2, OCT4, NANOG, SSEA3, 4 
and TRA1-60 and TRA1-81 confirming the successful reprogramming 
(Figure 14). Karyotypes were normal and the correct identity of the 
cells were confirmed by DNA fingerprinting.  
 
 
 
 
Figure 14: Immunocytochemical analysis of the expression of pluripotency markers in 
human SMA iPSCs. iPSCs colonies stained positive for the pluripotency markers 
SOX2, TRA160, SSEA4 and OCT4, confirming the acquisition of a proper phenotype 
after viral reprogramming 
 
 
Once the line was stabilized, SMA iPSCs were treated with n with the 
different novel MO oligomers (20ug) by nucleofection following the 
same method employed for the HeLa cells. After treatment, iPSC cells 
were collected at different time points: 72h, 7 days and 21 days order to 
test the time/efficacy curve. 
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We performed a proteomic analysis with western blot. MO-B and D 
were the two most effective oligomers in up-regulating the SMN protein 
level among the four compounds and, also in this case, the co-
administration of MO-B + MO-D was more effective than the treatment 
of the single oligomers at the same dose 72h after nucleofection 
(Figure 15). 
 
 
 
 
Figure 15: Western blot (upper figure) and densitometric analysis (bottom figure) of 
SMA iPSCs treated with different MO sequences and harvested 72h after treatment 
showed that the co-administration of MO-B + MO-D was more efficient than other MO 
sequences in up-regulating SMN level and it was similar to MO-10-34 
 
Immunocytochemical analysis of iPSCs harvested 72h after treatment 
(Figure 16) demonstrated that the gems/nuclei ratio was higher in the 
cells treated with MO-B + MO-D (mean ratio =0.55) and was proved to 
be statistically significant by one-way ANOVA and post-hoc Tukey’s 
test (p=0.0011), confirming the result obtained in wild-type cells 
(Figure 17). 
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Figure 16: Immunocytochemical analysis of treated SMA iPSCs. Nuclear gems (green) 
were detectable in all treated cells and the greatest increase in the number was seen 
after the co-treatment with MO B + MO D. Nuclei are labeled with DAPI 
 
 
Figure 17: Comparison of the means of gems/nuclei ratio in human SMA iPSCs 
treated with different MO sequences. The greatest increase was seen after the co-
treatment with MO B + MO D 
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In order to assess whether the splicing correction effect was maintained 
after multiple replication cycles, we collected treated iPSC cells at 
different time of harvesting after nucleofection. The co-treatment with 
MO-B + MO-D oligomers allows to obtain higher level of SMN full-
length for a longer time period, as shown by western blot analysis of 
iPSCs collected after21 days from MO-nucleofection (Figure 18). 
 
. 
 
 
Figure 18: Western blot (upper figure) and densitometric analysis (bottom figure) of 
SMA iPSCs nucleofected with MO-B, MO-D or MO-B + MO-D and collected 72hours, 
7days and 21 days after treatment showed that the co-treatment with MO B + MO D 
maintained higher levels of SMN for a longer times frame.  
 
 
These results suggest that the combined administration of different MO 
sequences can act in a synergistic increasing their efficacy. 
Remarkably, the enhanced efficacy is clearly detectable evident despite 
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the total MO dose is equal to that used in the single sequence 
treatment. This finding is important in the design of future experimental 
therapeutic protocol with ASOs.  
 
4.3 TREATMENT OF IPSC- DERIVED SPINAL MOTOR 
NEURONS WITH MO-B+D AMELIORATE THE SMA 
DISEASE PHENOTYPE 
We analyzed whether MO-B+D treatment can up-regulate SMN level 
also in differentiated SMA iPSC-MNs ameliorating their phenotype. 
Differentiation of spinal MNs from all iPSC lines was obtained by a 
multistep differentiation method previously implemented for human 
iPSCs based on the exposure to RA and SHH. After 4–5 weeks, MNs 
were obtained that were positive for MN-specific markers including 
spinal cord progenitor antigens (HB9, ISLET1, and OLIG2) and pan-
neuronal protein (TuJ1, Neurofilament, and MAP2). The majority of 
these HB9/ISLET1-positive cells stained for Choline Acetyl Transferase 
(ChAT) and expressed the MN marker SMI-32, confirming the 
acquisition of a MN phenotype. At 10 weeks, we detected a decrease in 
the number of mature MNs in the untreated SMA-iPSC derived MNs 
respect to wt-iPSCs (P < 0.01, Figure 19). SMA-iPSC MNs that were 
exposed to MO-B+D exhibited increased survival and neurite length 
respect to MNs differentiated from SMA-iPSCs-MNs treated with 
control vector (P < 0.01, ANOVA). These data support the fact that 
SMA disease hallmarks in human SMA-MN caused can be rescued by 
SMN2 gene modulation using MO-B+D. 
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Figure 19: MO-B+D ameliorates the SMA phenotype in iPSC-MNs, increasing cell 
survival and neurite length in long-term cultures. 
 
4.4 NOVEL MO SEQUENCES ARE ABLE TO INCREASE 
SMN PROTEIN LEVELS IN SMA7 MICE 
The MO oligomers that resulted more efficacious in increasing SMN 
level in vitro models, were then tested in vivo in the SMA∆7 transegnic 
mouse model. Non affected heterozygous mice were injected with 
different sequences (MO-B, MO-D, MO-B + MO D or MO-(10-34)) 
along the therapeutic protocol design presented in the Materials and 
Methods section. A subgroup of animals was administered with the 
negative control sequence scr-MO. Injected animals were sacrificed at 
P7 and brains and spinal cords were collected for proteomic studies.  
Western blot analysis revealed increased level of SMN full-length in all 
MO-treated tissues as compared to negative controls. However, MO-B 
and MO-D in single administration failed to significantly increase SMN 
protein level. Instead, the combination of MO-B + MO D sequences 
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was able to significantly increase the SMN protein in the CNS of treated 
animals. It has to be notice that this combination was slightly less 
effective than MO-10-34 in the mouse brain (Figure 20 A and B), but 
more efficacious in the spinal cord (Figure 20 C and D). 
 
. 
Figure 20: Western blot (A) and densitometric analysis (B) of brain samples of SMA 
mice treated with the different MO sequences showed that the efficacy of co-
administration of MO B + MO D was similar to that obtained with MO-10-34. Western 
blot (C) and densitometric analysis (D) of brain samples of SMA mice treated with the 
different MO sequences showed that the of co-administration of MO-B + MO-D was 
more efficient than other sequences and MO-10-34 in up-regulating SMN. 
 
Our experiments confirmed that the inclusion of the exon 7 in the SMN2 
transcript is a suitable and efficient strategy to increase the SMN 
protein levels. Furthermore, the use of combined alternative MO 
sequences can improve the effect of SMN2 splicing modulation and 
have a powerful impact on SMN protein levels. 
 
 
A 
D 
B 
C 
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4.5 THE TREATMENT WITH THE TAT-MO IMPROVED 
THE SURVIVAL OF SMA MICE 
Despite being used in a wide range of human diseases as a promising 
strategy for their treatment, antisense oligonucleotides (ASOs) have a 
low cellular uptake and limited bioavailability. These issues can be 
overcome by conjugation with cell-penetrating peptides (CPPs), due to 
their ability to translocate across biological membranes, but this 
approach has never been explored in SMA. 
One of the first CPP that has been reported in the literature [153, 160-
162], and one of the most investigated in experimental settings, is the 
TAT peptide, so we choose it to explore the possibility and efficacy of 
the MO conjugation with CPP strategy for the improvement of ASO 
therapeutics.  
Our goal was to demonstrate that TAT-MO was able to cross the BBB 
in SMA treated mice, improving their survival. Usually, the mean 
survival of the untreated mice is 13 days, with the manifestation of the 
first symptoms of the disease at post-natal day 4 (P4). So we decided 
to treat the mice at post-natal day 5 (P5). 
Since in the past years we previously proved the efficacy of MO-(10-34) 
oligomers, we decided to link TAT peptide to this sequence. 
First, we injected TAT-MO compound directly into the central nervous 
system (CNS) of symptomatic SMA∆7 mice by intracerebroventricular 
(ICV) administration at P5, in combination with a subcutaneous (SC) 
administration at P5 and P7 (Table 4, Materials and Methods). 
We tested two different doses of TAT-MO: one subgroup of 
symptomatic SMA animals was injected with 6nmoles/each injection of 
the conjugate and the results obtained were compared to the ones 
obtained from a second subgroup injected with unconjugated MO, as 
control. Data analysis demonstrated a relatively modest increase in 
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survival (mean survival 27.8 days) of the TAT-MO injected mice, 
respect to the subgroup injected with unconjugated MO (mean survival 
25.2 days), even of the results do not reached significance. 
The other tested dose was 12 nmoles per each injection (same 
administration protocol), in order to observe a dose-dependent increase 
of survival. The maximum survival of the group treated with a higher 
dose was 104 days (mean survival: 47.14 days, Figure 21) compared 
to the unconjugated MO (mean survival: 41 days, Figure 21). We 
observed that the 5 mice treated with TAT-MO (12 nmoles) survived 
more than 50 days compared to 2 mice treated with unconjugated-MO 
(12 nmloes). 
Our data were statistically significant (χ2 =10.08; p=0.0015). These 
results support that the effects of the TAT-MO is dose-dependent. 
In general, we demonstrated that TAT-CPP had a promising 
safety/efficacy profile and, if conjugate to MO-10-34, was able to 
increase the survival of treated mice, enhancing the cellular uptake of 
MO oligonucleotides. 
These results represent the ground for the design of further 
experiments to select and validate new and more efficacious CPPs to 
improve the cellular entrance of ASO and their tissutal distribution, in 
particular in the CNS, even in symptomatic phase. 
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Figure 21: Survival curve of severe SMA mice treated with unconjugated MO or with 
TAT-MO by intrathecal injection. Mice treated with 6nmoles of TAT-MO showed a 
modest increase in survival compared to unconjugated MO. Mice treated with 
12nmoles of TAT-MO showed a significant increase in survival compared to 
unconjugated MO. 
 
 
4.6 CPPs-MO EFFICIENTLY INCREASED SMN AFTER 
LOCAL ADMINISTRATIONIN SMA 7 ANIMALS 
The encouraging findings obtained after the TAT-MO injection in SMA 
7 animals led us to test the capacity of other novel CPPs to promote 
the MO cell-entrance and the efficacy of MO-(10-34). We assessed the 
ability of different CPP-MO compounds to promote the correct inclusion 
of exon 7 in the SMN2 transcript in vivo. The final goal was to identify 
the best CPP-MO compound to test it further in a wider subset of SMA 
animals to obtain efficacy data. 
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We considered four different CPPs: TAT, two polyarginine peptides 
(calledR6 and r6) and the (RXRRBR)2-XB peptides, taking into account 
their efficiency and safety described in literature. 
A group of non-affected heterozygous SMA-∆7 animals was injected 
with unconjugated MO-10-34 or with scr-MO as negative control, while 
small pilot groups were administered with one of the four CPP-MO 
compounds by ICV administration at P1 and SC administration at P3 
(12 nmoles/dose, see Table 5, Materials and Methods). Injected 
animals were sacrificed at P7 and the brains and the spinal cords were 
collected for proteomic investigation.  
Western blot analysis revealed that all the considered CPP-MO 
compounds were able to efficiently up-regulate the SMN protein level 
respect to scr-MO, as illustrated in Figure 22. Moreover, all the CPP-
MO compounds present a higher activity respect to unconjugated MO-
(10-34) (Figure 22). In the brain only R6-MO was slightly less efficient 
than the others, while RXR-MO conjugate was the most efficient in 
spinal cord, with up to three-fold up-regulation respect to scr-MO 
(Figure 17 C and D). 
Overall we demonstrated that the conjugation of MO with the CPPs 
enhanced its effect on SMN expression into the CNS after ICV 
administration. 
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Figure 22: Western blot (A) and densitometric analysis (B) of brain samples of SMA 
mice treated with the different CPP-MO conjugates, unconjugated MO or scr-MO by 
intrathecal administration showed that all the CPP- MO conjugates were more 
efficacious than unconjugated MO and TAT-MO and RXR-MO were the most 
efficacious ones. Western blot (C) and densitometric analysis (D) of spinal cord 
samples of SMA mice treated with the different CPP-MO compounds, unconjugated 
MO or scr-MO by intrathecal administration showed that RXR-MO was the most 
efficacious conjugate as compared to unconjugated MO. 
 
 
4.7 CPPs-MO EFFICIENTLY INCREASED SMN AFTER 
SYSTEMIC ADMINISTRATIONIN SMA7 ANIMALS 
One of the critical aspect of ASOs approach is their limited intracellular 
uptake and scarce tissue bioavailability after systemic intravenous 
injection, in particular for the presence of the blood-brain barrier (BBB), 
which is a major constraint to their use as therapeutics. 
Our aim was to asses if the conjugates CPP-MO were able to cross the 
BBB reaching the brain and the spinal cord when they were 
administered systemically, increasing SMN levels. 
We used the intravenous injection as systemic administration of MOs. 
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Per each CPP-MO, one group of treated mice received at P1 12 
nmoles of the conjugate (Table 5, Materials and Methods section). 
CPP-MO injected animals were sacrificed at P7 and their brains and 
spinal cords were collected for proteomic studies. The results obtained 
from western blot analysis of the brains demonstrated that MO linked to 
the TAT or R6 peptide presented a slightly increased capacity to cross 
the BBB and enter the CNS after systemic intravenous administration. 
In fact, TAT-MO and R6-MO were able to moderately up-regulate the 
SMN protein full-length protein level in the CNS of treated animals. On 
the other hand, the link of MO with the r6 or RXR peptides significantly 
enhanced the ability of MO to raise the expression of the SMN protein 
(more than 2.5-fold) after IV injection respect to scr-MO and 
unconjugated MO (Figure 23 A and B). 
 
 
 
Figure 23: Western blot (A) and densitometric analysis (B) of brain samples of SMA 
mice treated with the different CPP-MO compounds, unconjugated MO or scr-MO by 
intravenous injection showed that all the CPP- MO conjugates were more efficacious 
than unconjugated MO and r6-MO and RXR-MO were the most efficacious ones. 
Western blot (C) and densitometric analysis (D) of spinal cord samples of SMA mice 
treated with the different CPP-MO conjugates, unconjugated MO or scr-MO by 
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intravenous administration showed that RXR-MO was the most efficacious among the 
tested conjugates. 
 
The results from the spinal cord revealed that the TAT-MO, R6-MO and 
r6-MO are able to efficiently up-regulate the SMN expression injected 
animals respect to scr-MO-treated animals and were slightly more 
efficacious than unconjugated MO. Overall, the RXR-MO compound 
resulted to be the most potent (Figure 23 C and D). 
These data support our initial idea that CPPs can promote the entrance 
of MO into the CNS after systemic intravenous injection improving its 
efficiency. Furthermore, data proved that IV way of delivery is 
promising and could have comparable or even greater efficacy than 
CSF direct delivery, with the advantage of a reduced invasiveness. 
 
4.8 NEUROMUSCULAR AND SURVIVAL ANALYSES 
AFTER CP-MO TREATMENT 
The goal of this study is to identify the most efficient CPP-MO that will 
be further evaluated in a larger cohort of mice to evaluate its effect on 
survival, neuromuscular function and neuropathology of symptomatic 
homozygous SMA mice. As a matter of fact, the final aim of the project 
is to find a strategy to increase the efficacy of MO in symptomatic 
stages of the disease that usually correspond to the time of diagnosis. 
Since all the CPPs tested were able to increase MO efficacy, we 
selected RXR and r6 for the experiments on homozygous mice, 
according to their high efficiency and low toxicity. The treatments are 
ongoing.  
We will inject heterozygous SMA mice(P5) with r6-MO or RXR-MO 
(12nmoles/g) by IP injection. The mice will be sacrificed at p14 and a 
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western blot analysis to evaluate the SMN level in SC and Brain will be 
performed in order to evaluate the efficacy of the conjugates. 
Subsequently, homozygous SMA mice will follow the same treatments. 
They will be monitored for survival and motor function, assessed by 
testing the righting reflex and their performance at the hind-limb test 
(Tube test) and the rotarod test. 
At P6, SMA homozygous animals were clearly unable to perform the 
righting test. This assay consisted of placing the mouse in supine 
position on a flat surface and recording the time it took to turn over onto 
an upright position, or to “right” itself, by standing on all four paws. As 
expected heterozygous and WT controls were properly able to perform 
the task. 
We performed also the tube test. As expected homozygous SMA 
animals received a Hind-Limb Score (HLS) of 0 or 1, accordingly to 
their severe neuromuscular defects.  
We investigated also the rotarod assay, and as expected homozygous 
SMA mice never reach the age to be able to be tested (>1 month of 
age). 
The experiments presented in this section are still under analysis. It is 
warrants to notice that CPP-MO treated mice that have been up to now 
examined presented a significantly extended survival. Remarkably they 
present a reliable amelioration in their neuromuscular abilities as 
evaluated by behavioral analyses. CPP-treated animals are able to 
stand and freely ambulate exploring the surrounding environment in a 
comparable way to healthy wild-type mice. All of them were capable to 
complete the righting reflex test even after P6 (Figure 24). 
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Figure 24: None of the untreated mice (left) was able to right themselves after 
postnatal day 6 (P6) while R6-MO treated mice can perform the task even after P6. 
 
CPP-mice received a mean HLS score of 2 or 3 and some of them 
could even perform the rotarod test in a similar way as wild-type do. Up 
to now our best results were observed in animals injected with the r6-
MO conjugate by local administration. One of these mice has a survival 
of >4 months, could ambulate and was undistinguishable respect to 
unaffected wild-type mice. It obtained a HLS score of 3 and could 
successfully perform the rotarod test (Figure 25). 
 
 
 
Figure 25: MO treated mice was able to complete the rotarod test and presented an 
overall aspect similar to healthy wild-type mice.  
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5. DISCUSSION 
Translational medicine advancement has been widely expected for a 
increasing number of human genetic and neurological diseases. Of 
these, spinal muscular atrophy (SMA) is the best placed condition to 
gain on advances in therapeutics development in the near future. Over 
the past decade several different treatment strategies for SMA, in 
particular for upregulating SMN level have been developed in several 
laboratories and now are entering in the clinical stage. Specifically, the 
use of Antisense Oligonucleotides (ASOs) or small molecules as a tool 
to correct the alternative SMN2 splicing seems to be the most 
interesting strategy. 
In particular, the first and only approved drug for SMA, Nusinersen, is 
an ASO that regulates the splicing of SMN2 promoting the production 
of a functional protein. In this study, we used a modified ASO, called 
Morpholino (MO), in which the phosphordiamidate link to the 
Morpholino ring improves its safety and pharmacokinetic profile. The 
characteristics who make the MO better than ASO are the stability into 
cells and the resistance to metabolic degradation [163]. The 
mechanism of action of MO is based on a steric block on the mRNA, 
that interferes with the assembling of the splicing machinery at the 
specific mRNA target motif. The efficacy of this process is guaranteed 
by the perfect complementarity with the target sequence and by the 
number of nucleotides in the MO sequence. Consequently, a 
fundamental step in developing a MO-mediated splice-correction 
approach is the selection of the best target sequence. Furthermore, the 
delivery of a combination of two different MO oligomers was not been 
yet tested in vitro or in vivo. 
The primary goal of this project was to find and test new MO 
sequences with a better efficiency in comparison to MO-(10-34). We 
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designed four novel oligomers (called MO-A, B, C, D) to match the ISS-
N1 region, in the SMN2 intron 7. However, while MO-A and MO-B 
oligomers are complementary to the target motif, MO-C and MO-D 
sequences bind it only for the first 10 nucleotides. 
Usually, the oligonucleotides should prevent the assembly of the 
splicing machinery, leading to exon 7 retention, while, for MO C and 
MO D, we suppose that their free oligonucleotide tail can cause a more 
efficacious steric block effect, preventing exon 7 splicing. The new 
sequences were tested in vitro on wild-type human cell lines and on 
iPSCs reprogrammed from fibroblasts of SMA type 1 patients. We 
tested the novel sequences also on iPSC-derived MNs. We observed 
that there was a relative variability in the ability of the different MO 
sequences to up-regulate the SMN protein levels. Of these, MO-B and 
MO-D were the most potent compounds, allowing the greater 
expression of gems in cell nuclei and full-length SMN. Due to the 
positive results of these two sequences, we decided to combine them 
in a single administration, maintaining the same total dosage. Data 
obtained showed that the co-co-administration of MO-B plus MO-D was 
more effective than the treatment with a single MO oligomer, and also 
than the already validated MO-(10-34). The collection of iPSCs at 
different time points after treatment with MO-B, MO-D and MO B+ MO 
D was useful to analyze the SMN protein levels during time. All the 
treatments showed an increase of SMN also after 21 days after the 
nucleofection, even if the most efficient time point was 72 hours. 
Remarkably, we demonstrated also that MO B+D combination is able 
to increase SMN protein and rescue neuropathological features of SMA 
iPSC derived MNs, the cells that are selectively affected in SMA. 
The sequences that performed better in vitro were tested in vivo in 
heterozygous SMA7animalsin respect to that treated with the MO-(10-
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34) oligomer. Animals were injected intracerebroventricularly (ICV)and 
subcutaneously (SC) at P1 and again SC at P3. The findings generated 
in in vivo settings were in line to those demonstrated in vitro and they 
confirmed that the co-administration of MO B + MO D was more 
effective than the treatment with MO B or MO D alone in up-regulating 
the SMN full length protein in the brain and spinal cord of SMA mice. 
Furthermore, after the administration of MO B + MO D, the SMN levels 
were higher in the spinal cord of treated animals respect to those 
treated with MO-10-34. 
We hypothesized that the reason of the enhanced efficacy of MO B and 
MO D could be the different way in which they match the ISS-N1 
region. In fact, while MO B perfectly matches the target sequence, the 
MO D has an unpaired nucleotide tail that could account for an 
increased steric block action of MO-D itself. Our idea is that this 
strategy has two positive effects on the clinical advancement of this 
therapy. From one side we have an increase of the efficacy of the MOs, 
while on the other side these sequences can achieve the same 
biological effects using a lower dose. Our promising results should be 
validated by conducting other in vivo experiments in order to test the 
toxicity and the efficacy on the SMA phenotype of these new MO 
sequences. 
Another goal of our study is to improve the poor in vivo bioavailability of 
ASOs. In fact, despite the positive aspects of ASOs, such as their 
suitability to treat a wide range of human diseases, they have some 
limitations that have been improved by chemical modifications. The 
poor stability and their toxicity have been enhanced substituting the 
phosphorothioateribose backbone with a phosphorodiamidate-linkage 
morpholino backbone, making them refractory to metabolic 
degradation. However, the route of administration and the distribution in 
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human tissues are still the major obstacles of this therapeutic 
approach. The critical step of ASOs in reaching their target is the 
crossing of different biological barriers, like endothelial cells of small 
blood vessels, the plasma membrane and the nuclear membrane. But 
the most difficult passage is through the brain blood barrier(BBB) to 
reach the Central Nervous System (CNS). The structure of the BBB 
makes it highly selective for the transfer of macromolecules from the 
blood stream to the CNS. This is the reason why large and hydrophilic 
macromolecules are usually injected directly into the cerebrospinal fluid 
to act on the CNS. 
A promising strategy to facilitate the delivery of ASOs is the application 
of cell-penetrating peptides (CPPs). We explored if the conjugation of 
CPPs to MO oligomers allow them to easily cross the BBB after a 
systemic non-invasive intravenous injection and promote their efficacy 
and distribution into the CNS of SMA mice. 
To validate our thesis, we first conjugated MO-10-34 to the TAT 
peptide, as it is the best studied peptide to date and allows the 
penetration of different molecules through a mechanism of endocytosis. 
Moreover, the positive charge of pTAT can help the biodistribution 
through the brain [160]. 
Another critical issue is the therapeutic window of the disease. All 
research groups agree on the fact that the early administration of MO is 
more effective than late administration. But the presymptomatic 
diagnosis of the pathology is not always possible. For these reasons 
we decided to treat the mice at P5 and P7. Early results of the 
administration of unconjugated MO at these ages showed a reduction 
in amelioration of the phenotype and a reduced extension in the 
survival compared to the early delivery (P0 and P3). The explanation of 
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these data could be due to the leakiness of the BBB of the neonatal 
mice.  
The low biodistribution of unconjugated MO and the low efficacy of the 
P5/P7 treatment allowed us to test whether the conjugated TAT-MO is 
more efficient that unconjugated MO when they were administered at 
P5 and P7. 
We treated two groups of homozygous affected SMA mice by ICV 
injection plus SC injection at P5 and P7 and with another SC injection 
at P7 and we compared these results with the two obtained using the 
unconjugated MO. The first group received a dosage of 6 nmoles per 
injection. Simultaneously, the other group was treated with 12 nmoles 
per injection of TAT-MO conjugate, to verify if the response could be 
dose-related. Data showed a modest increase in lifespan in mice 
treated with a lower dose of TAT-MO compared to unconjugated MO, 
while a significant increase in survival for the group treated with 12 
nmoles of the conjugate was observed. 
Interestingly, we noted that the purity of the TAT peptide strongly 
influenced the outcome of treated mice. Indeed, we observed a high 
toxicity (almost all the mice died within few days after the treatment) 
with a batch of TAT peptide that next revealed a lower purity degree, 
while no lethal toxicity was found in the mice groups treated with the 
other batches. We excluded the data obtained with the batch that was 
not well purified. As described by Moulton[79, 154, 164],if TAT was 
administered as a free peptide, it showed a dose-dependent effect that 
should not exceed the dose threshold to ensure safety. Thus a 
chromatography purification is necessary to eliminate the excess of 
free peptide. 
Our positive results allowed us to choose TAT and three other cationic 
CPPs (named R6, r6 and RXR) to be conjugated with MO-10-34 and to 
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test their ability to cross the BBB, increasing the production of full-
length SMN protein. 
The R6 and r6 polyarginine CPPs are shorter and simpler than TAT 
[93]. They are made up by six covalent bounded arginine residues and 
differ only for the configuration of the amino acids: L enantiomeric 
configuration for R6 and D enantiomeric configuration for r6. Their 
efficiency is expected to be comparable to that of TAT peptide [114]. 
(RXRRBR)2 XB is the other peptide chosen because it has been 
reported to be able to cross the BBB and to successfully deliver ASOs 
to the brain and cerebellum of mice after a systemic administration 
[165]. The positive aspects of this peptide are its good safety and 
efficacy profile also in vivo, with no signs of toxicity reported. All these 
data provided a good background for the selection of the most efficient 
CPP for the delivery of our MO sequence. 
At first we treated a small pilot group of heterozygous mice with the four 
conjugates, the unconjugated MO and scr-MO (as control) in order to 
select the most efficient one. We tested two routes of administration: 
the local and the systemic one and we quantified the SMN protein 
levels in brain and spinal cord by western blot. After ICV injection, all 
the four CPP-MO conjugates increased the SMN levels more than 
unconjugated MO. In particular, RXR-MO was the most efficacious in 
the spinal cord (up to 3-fold compared to scr-MO) and its efficacy in the 
brain was comparable to that of the other conjugates. After IV injection, 
the best results were obtained after r6 and RXR conjugates 
administration in the brain (more than 2.5-fold), while in the spinal cord 
the most efficacious conjugate was RXR-MO. Our results showed that 
this strategy can be suitable to enhance the pharmacokinetic profile of 
MO, increasing its cell and tissue penetration after a local injection and 
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to cross the BBB more efficiently than unconjugated MO, growing its 
delivery to the CNS, after a systemic administration. 
Probably, the ability of the conjugates to increase their biodistribution 
and the cellular uptake is due to a longer retention of MO into cells, 
allowing a longer timespan between one intrathecal injection and 
another. This would result in less complication and side effects related 
to the procedure and considerably less discomfort to the patients. 
Moreover, the different capacity of the CPPs to cross the biological 
barriers is a fundamental characteristic in the selection of the most 
efficient one for the development of a non-invasive delivery strategy of 
MO oligomers. Further experiments on symptomatic homozygous SMA 
mice will be performed in order to obtain stronger evidence of the 
efficacy of our approach.  
Another issue is the route of administration of these conjugates. In fact, 
Hua et al. emphasized the importance of peripheral administration, 
while Burghes group supported the local CNS administration as the 
most efficacious method to restore the phenotype of treated mice [74, 
80]. 
Previous data from our lab showed that a single ICV injection of 
unconjugated MO was able to modify SMN2 splicing, increasing the 
survival of affected mice [83]. But the combination of local (ICV) and 
systemic (SC) injections determined an amelioration of NMJs, 
increased the MNs number and improved the muscular trophism. 
For all these reasons, mice will be treated with a local ICV injection 
and/or with a systemic IP injection, and we will evaluate the effect of 
the conjugates on survival and motor functions. The choice of 
symptomatic SMA mice is done in order to mimic the real therapeutic 
window in humans. In fact, SMA in rarely diagnosed in the pre-
symptomatic phase of the pathology. This means that we cannot 
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replicate in humans the positive results obtained in pre-symptomatic 
SMA mice. These experiments are still ongoing but our preliminary 
results showed an improvement of lifespan and motor performance of 
treated SMA mice, compared to the untreated ones. In particular, 
treated mice showed increased lifespan, could walk and explore the 
environment. They could perform different functional tests, like the 
righting reflex test after P6, achieved a Hind-limb Score (HLS) score 
from 2 to 3 and could complete the rotarod test. 
The best result we obtained to date in symptomatic mice is the one with 
r6-MO conjugate, administered by ICV delivery. One of these mice 
lived >4 months and showed a striking improvement in motor 
performance. It received a HLS score of 3, could successfully perform 
the rotarod test and behaved like unaffected littermates. 
Recently, it has been reported that the new family of Pip6 (a-f) CPPs 
could mediate the delivery of MO oligomers. In particular, Hammond 
and colleagues demonstrated that Pip6a could mediate the delivery of 
MOs in the CNS of SMA mice, increasing their lifespan [166]. 
When the symptomatic mice were treated with Pip6-MO by IV injection 
at P0, their lifespan increased of more than 450 days (average survival 
= 167 days), which is one of the best results reported in the literature to 
date. The interesting discovery was the dose-related response: when 
the pups were treated with a low dose of conjugate (10µg/g), which 
correspond to 1nmol/g, their motor functions significantly improved. 
This dose is five times lower than the doses used in other studies and 
ten times lower than the dose used in our work, suggesting that this 
peptide is particularly efficient in crossing the BBB compared to the 
other tested CPPs. Since the critical part of the SMA therapy is to reach 
the CNS of patients at all age, Hammond and colleagues tested this 
compound in unaffected adult SMA mice harboring SMN2 allele. They 
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administered twice 18 µg/g of Pip6a-MO by tail vein injection in 7.5 wk 
old mice, and collected the tissues 7 days after the treatment. The 
analysis of FLSMN2 transcripts revealed an increase in brain, spinal 
cord, skeletal muscle and liver. However, the SMN protein levels were 
augmented in skeletal muscle and liver only, maybe due to the 
sensitivity of SMN protein detection method. The difference between 
our study and Hammond’s study is that we are testing all the 
compounds on affected SMA mice at P5 using a single administration 
dose and we will evaluate not only the increase of SMN levels, but also 
we will monitor the survival rate, the behavior and neuropathological 
analysis, in order to prove also the survival of MNs in spinal cord. 
Since SMA infants are usually diagnosed after symptom onset, the 
treatment of the disease in a symptomatic phase is a critical step for 
the translation of the therapy in a clinical setting. Our preliminary results 
opened the possibility to widen the therapeutic window with our new 
approach. 
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6. CONCLUSIONS 
Globally, the results of our experiments strongly support the feasibility 
of the MO-mediated therapy for SMA. The efficacy of MO has been 
improved with two techniques: the optimization of the target sequence 
and the co-administration of two different sequences. The results of 
these approaches produced a high percentage of full-length SMN 
protein. Moreover, the cellular uptake and the pharmacokinetic profile 
of MO have been enhanced by the conjugation of our validate 
sequence with CPPs, opening the possibility of a non-invasive 
administration of MOs. 
Our future plans are: 
1) to complete the experiments on treated symptomatic mice at P5 in 
order to select the best CPP, evaluating their phenotype and the 
survival rate. Behavior analysis will be performed as previously 
reported [53, 74, 80]. 
All injected animals will be monitored daily for clinical signs of disease 
such as morbidity, mortality and weight by blind observers. The 
average life span of SMA mice is 13.6±0.7[167], Kaplan-Meier survival 
analysis and log-rank test will be used for survival comparisons.  
 
2) to perform neuropathological analysis of symptomatic treated mice 
with methodologies previously described [53, 83] to define if the 
treatment ameliorates the cellular phenotypes, reducing the decline in 
motor neuron cell counts in the spinal cord and improving muscle 
trophism. In particular, the count of the number and the size of motor 
neurons will be performed analyzing the ventral horn of the spinal cord 
and the axons in the ventral roots. 
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SMA mice show a loss of muscle mass, and their myofibers are 
typically small with no change in the number of nuclei per fiber and no 
increase in the number of centrally localized nuclei [168]. Furthermore, 
the SMA mice present a reduction of myofibers possibly linked to the 
loss of function of SMN protein in muscle causing a decline of muscle 
regenerative capacity. Proximal and distal nerves and overall muscle 
pathology will be assessed, including total cross-sectional area and the 
diameter and number of myofibers. Myofibers from each muscle will be 
randomly selected the cross-sectional area of each myofiber will be 
measured and the average myofiber size per muscle for each animal 
will be calculated. In addition, we will perform morphometric analyses of 
the neuromuscular end plate by assessing labeled neuromuscular 
junctions (NMJs) on the hind limb and intercostal muscles of CPP-MO 
treated SMA mice. The NMJ from each muscle will be randomly 
selected and assessed under the microscope to quantify the number of 
collapsed NMJ for each muscle group per animal. 
 
These two points will allow us to understand which conjugate could be 
translated in clinic even if some tests in larger animals should be 
performed to confirm the data obtained in mice.  
 
3) to test new peptides recently described in the literature, exploring the 
the Neurotoxin of Clostridium TetaniC fragment (TTC) and on a new 
family of synthetic cationic CPPs identified as Pip. 
The neurotoxin, produced by the bacterium Clostridium Tetani, is 
produced as a single polypeptide and then cleaved into a light (L) chain 
and a heavy (H) chain which are linked to each other by a disulfide 
bond. 
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The toxin specifically binds to neurons, especially to MNs [388]. It 
enters in neurons at the level of NMJs and once it reaches the 
dendrites, it can spread to adjacent neurons through synapsis. The 
essential part of this toxin is the C-terminal of the H chain (also called 
Tetanus Toxin C fragment or TTC), which is able to bind neurons 
without any toxic effect. Due to this ability, TTC can be conjugated to 
different molecules [169-171] and can be used as a carrier to target 
specific neurons. 
We believe that TTC-mediated MO oligomers delivery to MNs could 
give positive results, and in general this strategy can be useful to 
deliver therapeutic molecules to CNS by bypassing the BBB for the 
treatment of neurological diseases. 
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